Comparing the Impact of Control Strategies on Mathematical Models of \u3ci\u3eClostridium difficile\u3c/i\u3e Transmission by Stephenson, Brittany Christine
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
Doctoral Dissertations Graduate School
8-2018
Comparing the Impact of Control Strategies on
Mathematical Models of Clostridium difficile
Transmission
Brittany Christine Stephenson
University of Tennessee, bsteph13@vols.utk.edu
This Dissertation is brought to you for free and open access by the Graduate School at Trace: Tennessee Research and Creative Exchange. It has been
accepted for inclusion in Doctoral Dissertations by an authorized administrator of Trace: Tennessee Research and Creative Exchange. For more
information, please contact trace@utk.edu.
Recommended Citation
Stephenson, Brittany Christine, "Comparing the Impact of Control Strategies on Mathematical Models of Clostridium difficile
Transmission. " PhD diss., University of Tennessee, 2018.
https://trace.tennessee.edu/utk_graddiss/5040
To the Graduate Council:
I am submitting herewith a dissertation written by Brittany Christine Stephenson entitled "Comparing
the Impact of Control Strategies on Mathematical Models of Clostridium difficile Transmission." I have
examined the final electronic copy of this dissertation for form and content and recommend that it be
accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in
Mathematics.
Judy D. Day, Major Professor
We have read this dissertation and recommend its acceptance:
Nina H. Fefferman, Michael W. Frazier, Suzanne M. Lenhart
Accepted for the Council:
Dixie L. Thompson
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)
Comparing the Impact of Control
Strategies on Mathematical Models of
Clostridium difficile Transmission
A Dissertation Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville
Brittany Christine Stephenson
August 2018
c© by Brittany Christine Stephenson, 2018
All Rights Reserved.
ii
I dedicate this dissertation and the completion of my degree to my incredibly giving and
patient parents, selfless boyfriend, and supportive siblings. Without their unceasing love,
encouragement, and guidance, I would never have made it this far. I thank them each for
believing in me and pushing me to accomplish my goals even (and especially) when I
doubted myself.
iii
Acknowledgments
I must begin by acknowledging both of my advisors, Judy Day and Suzanne Lenhart, for
their guidance and encouragement throughout the entirety of my time in graduate school. I
will never be able to thank them enough for going above and beyond their duties to ensure
my success. To Judy, thank you for all the pep talks and encouraging words you gave me
over the course of our time together and thank you for the countless times you allayed my
stress and reminded me of my capabilities. You were the perfect combination of motivating
and encouraging, and I could not have asked for a better advisor or inspiration. Your care
and compassion carried me through some of my most stressful days. To Suzanne, thank you
for inspiring me every day with your dedication to your students and their success, ability to
balance a large number of projects with such ease, enthusiasm for women in mathematics,
and desire to impact future generations of mathematicians. Your passion and brilliance are
evident, and I am honored to have had the chance to work with you.
I would also like to thank my “non-mathematics” advisor, Cristina Lanzas, for guiding
me in my understanding of C. difficile. My project was motivated by Dr. Lanzas’s previous
work and was funded by the joint DMS/NIGMS Mathematical Biology Program through
NIH award #R01GM113239, of which she is PI. None of this would have been possible
without her or her expertise. To the other members of my committee, Drs. Mike Frazier
and Nina Fefferman, thank you for the time you gave to thoughtfully evaluating my work
and for your willingness to serve on my committee (especially to Dr. Frazier, who was on
sabbatical at the time).
My time as a graduate student at the University of Tennessee was funded through a
teaching assistantship and through the NIH award previously mentioned. I am very thankful
to have worked in such a supportive and collaborative mathematics department. To Joan
iv
Lind, thank you for your guidance and support in all of my pedagogical endeavors; I owe
my growth as an instructor to you. To Pam Armentrout, you are invaluable. Thank you
for all the times you talked me through stress and for all that you do for the mathematics
department. To my fellow graduate students, Betsy, Lindsey, Maggie, Kylie, Camila, Mark,
Grace, Kolin, Elise, Jimmy, and many others, thank you for all the chats, collaborations,
venting sessions, and “non-math” activities. I also have to thank my undergraduate advisor,
Dr. Ratnasingham Shivaji, without whom, I may not have pursued an advanced degree in
mathematics.
To my unwaveringly supportive boyfriend, Thomas, thank you for all the laughs you
bring me and for standing by me and encouraging me to continue throughout my time as a
graduate student; I could not have done this without you. To my parents, Chris and Jud, I
would not be the person I am today without your love, sacrifice, and support. Everything
I do is because of and thanks to you. To my brother, Matt, my career in mathematics is
thanks to your example and assistance, and you continue to inspire me every day. To my
sister, Kayla, thank you for being a constant source of support, friendship, and happiness.
To my best friends, Jaclyn, Megan, and Megan, your love and support have helped carry me
through this process. Finally, to my two loving and loyal dogs, Rudy and Corky, thank you
for never leaving my side during the late nights of work and for constantly bringing me joy,
even through the stress.
v
Abstract
The spore-forming, gram-positive bacteria Clostridium difficile can cause severe intestinal
illness. A striking increase in the number of cases of C. difficile infection (CDI) among
hospitals has highlighted the need to better understand how to prevent its spread. In this
dissertation, I discuss the development and structure of two different models of nosocomial
C. difficile transmission that we used to evaluate the efficacy of various control strategies
and to determine optimal interventions.
We begin with an update and modification of a compartmental model of nosocomial C.
difficile transmission to include vaccination. We then apply optimal control theory on this
epidemiological model to determine the time-varying optimal vaccination rate that minimizes
a combination of (1) disease prevalence and spread in the hospital population and (2) the
cost, in terms of time and money, associated with vaccination. Various hospital scenarios are
considered, such as times of increased antibiotic prescription rates and periods of outbreak,
to see how such scenarios affect the optimal vaccination rate. By comparing the values of
our objective functional with constant vaccination rates to those with time-varying optimal
vaccination rates, we illustrate the benefits of time-varying controls.
The second model is an agent-based model that also simulates the transmission of C.
difficile in a healthcare setting. This model explicitly incorporates healthcare workers
(HCWs) as vectors of transmission, tracks individual patient antibiotic histories, incorporates
varying risk levels of antibiotics with respect to CDI, and tracks contamination levels of
ward rooms by C. difficile. Using this model, we evaluated the efficacy of a variety of
control interventions and combinations of interventions on reducing C. difficile nosocomial
colonizations and infections. The control techniques included two forms of antimicrobial
vi
stewardship, increased environmental decontamination through room cleaning, improved
HCW compliance, and a preliminary assessment of vaccination.
vii
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Chapter 1
Introduction
1.1 Background
In the United States, one of the most common causes of healthcare-associated infections
(HAIs) is the spore-forming, toxin-producing bacteria Clostridium difficile [50, 42]. In fact,
C. difficile has surpassed Staphylococcus aureus as the leading cause of nosocomial infections
[42]. Although C. difficile was first identified in the 1930s and has since been more intensely
studied beginning in the 1970s, there is still difficulty diagnosing, treating, and preventing C.
difficile infection (CDI) [19]. Between 2000 and 2010, the number of hospitalizations for CDI
among adults in the U.S. doubled [50]. This increase in both incidence and severity coincided
with the emergence of the epidemic NAP1/B1/027 strain, which is a highly virulent strain
[56]. In 2011, C. difficile was estimated to cause approximately 453,000 incident infections
and was linked to approximately 29,000 deaths [50]. For acute care facilities alone, the
estimated costs associated with C. difficile infection are as much as $4.8 billion [50], which
has placed a significant burden on healthcare facilities.
C. difficile spores are commonly found in the environment of healthcare facilities and are
transmitted through the fecal-oral route [48]. Symptomatic and asymptomatic individuals
shed C. difficile spores, and if ingested by a susceptible person, the spores can survive
the acidity of the stomach and reach the large intestine, where C. difficile can colonize.
Typically, the normal gut microbiota prevents C. difficile colonization by competing for
nutrients and producing inhibitory compounds against C. difficile. Antibiotics disrupt the
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normal gut microbiota, facilitating the colonization of C. difficile. Hence, use of antibiotics
is the strongest risk factor for developing CDI, and almost all antibiotics have been linked
to CDI [48]. With advanced age comes an increased risk of contracting CDI [48]. Toxins
A and B are responsible for most of the clinical manifestations of CDI including diarrhea,
abdominal pain, and bloating [48]. Once C. difficile reaches large numbers in the colon, both
toxins A and B are produced by C. difficile [19]. In response, some people will be able to
mount their own immune response and fight off the toxins. These individuals will become
asymptomatic carriers and never experience clinical symptoms [45].
Strategies to control and prevent CDI include antimicrobial usage restriction and
stewardship and methods to prevent the patient from exposure to C. difficile [18]. Current
practice includes identifying patients who have clinical CDI, putting them into isolation,
and taking proper contact precautions such as wearing gloves and gown, as well as vigilant
hand-washing with soap [18]. C. difficile cannot be eliminated by routine surface cleaning
nor by alcohol-based hand sanitizers, but washing with soap and water has been shown to
decrease C. difficile spores [48]. Worth noting is the fact that the large increase in CDI in the
early 2000s coincides with the expanded use of alcohol-based hand sanitizers in healthcare
settings [19].
In spite of these current practices, a notable difficulty in studying nosocomial C.
difficile transmission arises because many colonized patients, who also shed C. difficile
in their feces and contribute to transmission, are asymptomatic. Over the years, there
have been discrepancies in determining the relative contributions of asymptomatic carriers
versus those of symptomatic patients. In the 1980s, studies were conducted by [9] that
concluded symptomatic CDI patients were the main source of C. difficile transmission.
Therefore, protocol often focused on isolating and taking proper contact precautions with
only symptomatic CDI patients. Such protocol included healthcare workers’ wearing gloves
and gowns when interacting with symptomatic patients and the intense cleaning of their
hospital rooms after symptomatic patients were discharged [48]. However, since these
studies were completed, changes in the epidemiology of C. difficile may have altered the
relative contributions of symptomatic CDI patients and asymptomatic carriers [45, 80].
Typically, healthcare facilities are unable to readily identify asymptomatic patients, so their
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contribution to the spread of C. difficile is often more significant than that of symptomatic
patients because healthcare workers may not follow proper contact protocol when interacting
with them [19]. Therefore, it would be beneficial to identify not only symptomatic patients,
but also asymptomatic ones. There are two types of asymptomatic patients: those who are
able to mount an immune response and avoid infection and those who are unable to mount
an immune response, which leaves them vulnerable to contracting CDI.
Current treatment for patients experiencing CDI symptoms includes antimicrobial
therapy, specifically with metronidazole or vancomycin [73]. Data have indicated that
symptoms are resolved in 80% of patients treated with one of these antibiotics [45]. However,
the antibiotics may also disrupt the normal gut microbiota and lead to recurrence of CDI
upon cessation of treatment [73]. Therefore, it is often recommended that all antibiotic
usage be stopped if possible to allow the gut microbiota to return to normal, which is often
sufficient for controlling C. difficile [73]. Active vaccination is also being considered with the
current clinical trial testing of three toxoid vaccines that would fight off the main virulence
factors of C. difficile, toxins A and B. Initial trial phases have shown signs of efficacy [84],
and the hope is for at least one of these vaccines to be approved for implementation.
Since C. difficile infection and colonization have been acknowledged as a significant
burden to healthcare facilities [73], there is a strong need to better understand the
transmission and subsequent infection by C. difficile in order to prevent its spread.
Mathematical models have been used to successfully amalgamate theory with procedures and
data in order to simulate disease dynamics and predict emerging behaviors [46]. The goal of
my work is to develop mathematical models of C. difficile transmission in order to gain insight
into the dynamics of its spread, explore the role of the environment in its transmission, and
to assess optimal intervention strategies. Because the majority of CDI cases are nosocomial
[48], this dissertation focuses on modeling the within-hospital transmission of C. difficile.
Two different types of models are considered, and each incorporate different underlying
assumptions about how C. difficile is spread.
3
1.2 Compartmental epidemiological model
The first model we developed is a modification of the compartmental model of C. difficile
nosocomial transmission in [45], consisting of ordinary differential equations (ODEs) that
group patients into classes based on their disease status (similar to the classic SIR model [6]).
The focus of this ODE model is on assessing the impact of vaccination on CDI transmission.
With a C. difficile toxoid vaccine still in testing, this model was our first exploration into
how a vaccine could theoretically affect the spread of CDI in a healthcare setting. A major
underlying assumption of this model is the direct transmission of C. difficile from an infected
patient to a susceptible patient, i.e., without the explicit modeling of an environmental
reservoir or healthcare workers.
Using this model, we aimed to determine the optimal time-varying rate of vaccination that
minimized both the cost associated with a vaccination program and the overall impact of the
disease, including the prevalence, incidence, and transmission. Obtaining the optimal rate
of vaccination involves assessing trade-offs between vaccinating a large number of patients to
control the disease while also keeping the associated cost low. To answer this, we used optimal
control theory to find the optimal rate of vaccination that minimized our objective functional
subject to the system of ordinary differential equations that simulated transmission. We
formulated the objective functional to represent our goal of controlling the vaccination rate
in a way that minimizes the cost and the overall impact of disease. This model and the
corresponding optimal control problem are detailed in Chapter 2. An overview of optimal
control theory is given in the following section.
1.2.1 Optimal control theory
Optimal control theory involves steering a dynamical system to a desired state by adjusting
the values of a control or multiple controls [70, 49]. The underlying dynamic system
being steered can be represented by ordinary differential equations, partial differential
equations, discrete equations, stochastic differential equations, integro-difference equations,
or a combination of discrete and continuous systems [49]. We will focus on an underlying
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system represented by ODEs. In the 1950s, Pontryagin and his collaborators developed the
theory of optimal control of systems of ODEs [70].
Suppose u(t) denotes a control and x(t) represents the underlying state dynamics and is
dependent on the control u(t). Then, we define x(t) by the differential equation:
x′(t) = g(t, x(t), u(t)). (1.1)
This dependence of the state system on the control means that a change in the control value
engenders a change in the state solution [49]. An optimal control problem involves solving
for the time-varying control, u(t), and corresponding state, x(t), that maximize the objective
functional, formulated to balance the tradeoffs being assessed [49]. In general, we want to
find the optimal control, u∗(t), that satisfies the following:
J(u∗) = sup
u∈U∗
J(u), (1.2)
where U∗ is the set of admissible controls and
J(u) =
[
φ(x(t1)) +
∫ t1
t0
f(t, x(t), u(t))dt
]
, (1.3)
subject to (1.1) with x(t0) = x0 and x(t1) unrestricted. J(u) represents the objective
functional. If an optimal solution exists and is unique, we refer to it as the optimal control
and denote it by u∗(t). The solution to the state system that corresponds to the optimal
control is denoted x∗(t) and is referred to as the optimal state. Together, (u∗(t), x∗(t)) are
referred to as an optimal pair [49].
Solving an optimal control problem involves solving a set of necessary conditions. First,
one must establish that an optimal control exists. If it is determined an optimal pair exists,
then Pontryagin’s Maximum Principle [70] provides necessary conditions for solving for
(u∗(t), x∗(t)). Pontryagin’s Maximum Principle introduces an adjoint variable(s), denoted
λ(t), to link the state equation(s) to the objective functional, J(u). This concept is similar
to the idea of introducing Lagrange multipliers to solve constrained optimization problems in
multivariable calculus. The Maximum Principle takes the original problem of finding u ∈ U∗
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that maximizes J(u) subject to the state equation (1.1) with specified initial conditions and
transforms it into the problem of maximizing what is referred to as the Hamiltonian with
respect to u, pointwise. The formal statement of the Maximum Principle follows below for
continuously differentiable functions f, g, and φ in their arguments and f and g concave in
u.
Theorem 1.1. Pontryagin’s Maximum Principle ([70]): If (u∗(t), x∗(t)) are an optimal
solution pair to (1.2) with (1.1), then there exists an adjoint variable, λ(t), such that
H(t, x∗(t), u(t), λ(t)) ≤ H(t, x∗(t), u∗(t), λ(t)), (1.4)
for all u(t) ∈ U∗ at each time t, where
H(t, x(t), u(t), λ(t)) = f(t, x(t), u(t)) + λ(t) · g(t, x(t), u(t)) (1.5)
is called the Hamiltonian and
λ′(t) = −∂H(t, x
∗(t), u∗(t), λ(t))
∂x
, λ(t1) =
dφ
dx
(x∗(t1)). (1.6)
Pontryagin’s Maximum Principle can also be extended to a system of n state differential
equations: x1, ..., xn. In this case, there would be n adjoint differential equations: λ1, ..., λn,
one for each state equation. The Hamiltonian would be defined as
H(t, x1(t), ..., xn(t), u(t), λ1(t), ..., λn(t)) = f(t, x1(t), ..., xn(t), u(t))
+ λ1(t) · g1(t, x1(t), ..., xn(t), u(t)) + ...
+ λn(t) · gn(t, x1(t), ..., xn(t), u(t)), (1.7)
where gi refers to the right-hand side of the i
th state differential equation, x′i(t). The adjoint
differential equations and corresponding transversality conditions would then be defined as
λi(t) = −∂H
∂xi
, λi(t1) =
dφ
dxi
(x1(t1), ..., xn(t1)), (1.8)
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at u∗, x∗1, ..., x
∗
n.
1.3 Agent-based model
The simplifying assumption of direct transmission of C. difficile from an infected individual
to a susceptible individual did not allow us to explicitly evaluate the role of a pathogen
environmental reservoir. Since C. difficile spores can survive for extended periods of time,
even years, in healthcare facilities [28], C. difficile in the environment plays a significant role
in transmission. Therefore, our second model, discussed in Chapter 3, incorporates the role
of environmental transmission through the explicit inclusion of the dynamics of healthcare
workers (HCWs). We then are able to assess the impact of various intervention strategies
while considering the contribution to transmission from an environmental pathway.
Often, models include simplifying assumptions that restrict their complexity in order
to maintain their mathematical tractability [72]. With agent-based models (ABMs), we
can remove many of these simplifying assumptions through the use of computer simulation.
Rather than modeling just the average behavior of a population, ABMs allow individuals
within a population to each be characterized by specific traits and events to be defined
and simulated on an individual-to-individual basis. These individual behaviors are then
simulated to observe overall system dynamics that arise over time, often referred to as
emergent behavior [72]. Interactions among agents (or individuals) are typically defined
locally, which adds a spatial component to the model. ABMs allow us to discern how the
overall behavior of a system is linked to individual behaviors. Another benefit of ABMs
is that they allow us to model processes that may be too complex to represent in a more
traditional equations-based model [72]. We have the freedom to include as much detail as we
want when developing ABMs; however, decisions and assumptions have to be made about
which individual characteristics, behaviors, and interactions to incorporate in the model and
which are not as influential on the overall system dynamics [72].
Of primary importance to pathogens with environmental reservoirs is spatial heterogene-
ity. Exposure to C. difficile depends on the varying survival and growth of the pathogen
on different hospital surfaces [34, 52], and control interventions often include a spatial
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component. For example, we may want to more stringently clean a room from which a
symptomatic patient was discharged than a room from which a healthy individual was
discharged. Not all rooms in healthcare settings receive the same frequency of contact
and level of cleaning and disinfection [15, 7, 22], so a more detailed assessment of control
interventions for environmentally transmitted pathogens necessitates a spatially explicit
model, such as an ABM.
The level of compliance of HCWs to proper hand-washing and contact protocol differs
by individual, and the level of environmental cleaning is also variant. ABMs allow for the
incorporation of varying individual compliance levels and are inherently stochastic in nature.
Thus, different outcomes at the population level can arise from similar starting conditions
due to the stochasticity of individual behaviors.
In Chapter 3, we describe the ABM we developed to include environmental transmission
in the spread of C. difficile in a healthcare setting. By modifying and expanding an ABM
originally created by Bintz et al. [5], we developed an ABM that includes individual antibiotic
histories of patients, environmental contamination of individual rooms, and HCWs as vectors
of transmission. The explicit addition of HCWs allows us to consider individual HCW
behaviors and to assess the impact of increased overall HCW compliance on the spread
of C. difficile spores. We use this model to explore the effect of individual intervention
strategies as well as to assess if there is an optimal combination of intervention strategies
for reducing nosocomial infection incidence and colonization by C. difficile. Investigating
how an environmental reservoir affects transmission of a pathogen is an ongoing assessment,
and with this work, we aim to gain traction in pinpointing where control efforts should be
concentrated.
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Chapter 2
Compartmental model of nosocomial
C. difficile transmission
2.1 Introduction
Many healthy individuals have antibodies against C. difficile toxins A and B, and these
antibodies have a protective effect against clinical disease [85]. In a prospective study,
patients with low levels of IgG antibodies against toxin A were at greater risk of developing
C. difficile-induced diarrhea [43]. Vaccination can be an important addition to the current
intervention strategies against C. difficile. Currently, several toxoid vaccines (i.e., vaccines
that confer immunity against C. difficile toxins) are being tested in clinical studies for
efficacy, effectiveness, and safety [51]. Toxoid vaccines can provide protection against clinical
diseases but not against C. difficile colonization. In [47], a simulation study looking at C.
difficile vaccination was found to be cost-effective for a range of risk, vaccine efficacies,
and vaccine cost in two populations: a target vaccination for patients with CDI undergoing
antibiotic treatment and universal vaccination on at-risk patients. Vaccination as an infection
control measure was not evaluated. Although vaccination with a toxoid vaccine may not
prevent colonization, it may reduce transmission in hospital settings.
In this chapter, our goal is to better understand how vaccination would affect the
transmission and prevention of CDI in a healthcare setting and also to determine the most
cost-effective way to implement a vaccination strategy. In order to accomplish this goal,
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Table 2.1: Patient transition states developed in [45]
State Infection status
R resistant to colonization
S susceptible to colonization
C− asymptomatically colonized without protection against CDI
C+ asymptomatically colonized with protection against CDI
D diseased (with CDI)
we use techniques of optimal control on a system of ordinary differential equations (ODEs).
See [27, 53, 16, 2, 30, 24, 61] for examples of the use of optimal control theory to design
vaccination strategies in ODE models of infectious diseases.
We begin in Section 2.2 by developing a compartmental model that describes the
movement of hospital patients in and out of seven CDI-related states. A control variable
representing the vaccination rate is incorporated into the system. Then, in Section 2.4,
we utilize optimal control techniques to determine the time-varying optimal rate at which
hospitals should vaccinate in order to minimize the disease prevalence, disease transmission,
and the related cost, in terms of both time and money. In Section 2.5, we discuss the results
of our numerical simulations. In particular, we determine optimal vaccination strategies
for various hospital statuses, such as times of high transmission of C. difficile and periods
of increased administration of antibiotic prescriptions. We also compare the value of the
objective functional with a time-varying vaccination rate to that with a constant vaccination
rate to determine the benefits of varying the vaccination rate with time. Finally, in Section
2.6, we discuss our conclusions based on the numerical results.
2.2 ODE Model
Because mathematical models of disease transmission provide a solid framework for
understanding the spread of disease, we begin by extending the mathematical model of
C. difficile transmission developed by [45] to include vaccination. The original model is a
system of ODEs that depicts C. difficile transmission within a hospital setting, where all
patients are divided into five transition states, measured in number of patients, according to
infection status as listed in Table 2.1.
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Table 2.2: Additional patient transition states for vaccinated patients
State Infection status
V vaccinated for CDI and not colonized
C+v asymptomatically colonized and vaccinated
Resistant patients (R) have not received antimicrobial treatment and have a normal
intestinal microbiota [39]. It is assumed that patients with a normal intestinal microbiota
are resistant to colonization since patients with a normal flora have a significantly lower
risk of developing CDI [45]. Susceptible patients (S) have received antimicrobial treatment
and are therefore susceptible to colonization. Colonized patients may or may not mount
a protective response. Those who are colonized, asymptomatic, and unable to mount an
immune response are labeled C− and could potentially develop CDI. C+ patients are also
colonized and asymptomatic, but they are able to mount an immune response and do not
become diseased. All C− and C+ patients are assumed to be colonized during their entire
stay at the hospital [58, 77], and both can transmit the disease to the susceptible population.
Diseased patients (D) are treated with antibiotics and either become susceptible again or
remain infected if treatment is unsuccessful.
In addition to the classes in the original model by [45], we will also consider two
additional transition states for vaccinated patients, listed in Table 2.2. In our model,
vaccination will be performed on patients in S, C−, and C+. As previously stated,
vaccination does not eliminate colonization from those who are in C− or C+. Because
colonized patients, even asymptomatic ones, contribute to the transmission of disease, it is
important to distinguish between those who are vaccinated and those who are vaccinated
but also colonized. For this reason, we consider two classes of vaccinated patients. It should
also be noted that although C+ patients are not at risk of contracting CDI, we still vaccinate
them because there is not a practical and quick method for distinguishing between C− and
C+ patients when deciding who needs vaccinating. Therefore, C+ and C+v have the same
infection status, but both of these classes are necessary in the model to keep track of who
has been vaccinated and to prevent the same patient from being vaccinated multiple times.
Because they have the same infection status, we assume the transmission coefficients for C+v
and C+ are equivalent.
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Patients can be discharged and admitted in any of the seven states, but in all cases
presented in this chapter, we assume that none of the patients are already vaccinated when
admitted. All transitions are modeled deterministically as the system of ODEs given in (2.1),
an extension of the model developed by [45]:
dR
dt
= arδN + θS − (α + kr)R
dS
dt
= asδN + αR + pεD − (θ + λ+ k + v)S
dC−
dt
= acnδN + (1− f)λS − (φ+ k + v)C−
dC+
dt
= acpδN + fλS − (k + v)C+ (2.1)
dD
dt
= adδN + φC
− − (pε+ kd)D
dV
dt
= avδN + vS − (λ+ k)V
dC+v
dt
= acvδN + v(C
+ + C−) + λV − kC+v ,
where the transmission rate is
λ = βc(C
− + C+ + C+v ) + βdD
and
N = R + S + C− + C+ +D + V + C+v .
To maintain a constant total population, we define δN similarly to that in [45], which allows
discharges to be balanced with admissions:
δN = krR + kS + kC
− + kC+ + kdD + kV + kC+v . (2.2)
The movement among states described by the system in (2.1) is illustrated in Figure
2.1. Details about each parameter are listed in Table 2.3; a similar table is found in the
work completed by [45] with a few modifications and updates made here. Parameter values
are based on hospital data or published literature. In particular, the restoration rate of
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Figure 2.1: Summary of movement among patient transition states with corresponding
parameters
colonization resistance, θ, is taken from [71]. The fraction of colonized patients that mount
an immune response, f , comes from [44], and both the treatment rate, ε, and the probability
of successful treatment, p, are taken from [57]. All remaining parameters are either based
directly on hospital data or are an adjustment of hospital data to reflect observed disease
incidence. More details on these adjustments are given in the following paragraphs.
At the time [45] developed their model, hospital data indicated that the proportion
of admitted patients that were asymptomatically colonized totaled 2%. Therefore, in [45],
acn = acp = 0.01. Since this time, new research in [1] has indicated that approximately 15% of
admitted patients were observed to be asymptomatically colonized upon arrival. We divided
this updated percentage into 9% admitted with protective response, acp, and 6% without
protective response, acn. Once these values were determined, the admission proportion for
susceptible patients was accordingly decreased by 13% from the value of 22% used in [45],
which updated as to 0.09 as listed in Table 2.3. The values for av and acv were assumed to
be 0 for all results presented. Once the admission percentages were all adjusted to match
updated observed rates, the transmission coefficients, βc and βd, and the clinical disease
rate, φ, were then adjusted so that the average number of observed incident cases of CDI
per month per ward was comparable to the value of 2.2 given in [45].
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Table 2.3: Model parameter descriptions and values
Symbol Description, units
Baseline
Value
ar
Proportion of admitted patients that are resistant,
dimensionless
0.75
as
Proportion of admitted patients that are suscepti-
ble, dimensionless
0.09
acn
Proportion of admitted patients that are colonized
without protective response, dimensionless
0.06
acp
Proportion of admitted patients that are colonized
with protective response, dimensionless
0.09
ad
Proportion of admitted patients with C. difficile
infection, dimensionless
0.01
av, acv
Proportion of admitted patients who are vacci-
nated and vaccinated who are colonized, respec-
tively, dimensionless
0
α Antibiotic prescription rate, per day 0.5
θ Restoration rate of colonization resistance, per day 0.033
βc, βd
Transmission coefficients for asymptomatic car-
riers and diseased patients, respectively, per
individual-day
10−6
f
Fraction of colonized patients that mount immune
response, dimensionless
0.6
ε Treatment rate, per day 0.1
p Probability of successful treatment, dimensionless 0.8
φ Clinical disease rate, per day 0.06
kr Discharge rate for resistant patients, per day 0.33
k
Discharge rate for susceptible, colonized, and
vaccinated patients, per day
0.15
kd Discharge rate for diseased patients, per day 0.068
v Vaccination rate, per day varied
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Table 2.4: Exploration of a biologically feasible range of values for vaccination rate, v
v % effectively vaccinated out of
total admitted (in 30 days)
2 73.46%
1 67.51%
0.5 58.07%
0.3 48.91%
0.1 27.24 %
0.05 16.33%
We define the vaccination rate v to be the effective vaccination rate, which encompasses
both effort and efficacy. To estimate a feasible range of values for the effective vaccination
rate v, we solved the system in (2.1) numerically for various v values and noted the resulting
percentage of patients who were effectively vaccinated out of the total number of patients
admitted over a 30-day period. A few of these scenarios are summarized in Table 2.4.
While determining this range for the vaccination rate, we decided for most simulations to
not consider cases in which significantly more than 50% of those admitted in 30 days were
effectively vaccinated. Therefore, we concentrate most of our focus on 0 ≤ v ≤ 0.3. Because
of the short time frame evaluated, we do not consider waning immunity.
For our simulations, we assume a hospital setting containing five wards of 30 beds each
for a total population of N = 150 patients, which is kept constant by assumption (2.2). The
initial conditions used were based on the admission proportions given in the list of parameter
values shown in Table 2.3; that is, we set R(0) = 112, S(0) = 14, C−(0) = 9, C+(0) = 13,
D(0) = 2, V (0) = 0, and C+v (0) = 0.
2.3 Existence and uniqueness
In this section, we will provide results about the existence, uniqueness, and non-negativity of
solutions to our system in (2.1) for a given initial condition vector in R7+. To begin, consider
the general initial value problem
x′(t) = f(x(t)) (2.3)
x(t0) = φ,
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where f : C → Rn is continuous, C ⊂ Rn is open, and φ ∈ Rn. Define R to be the following
rectangular region:
R = R((t0, φ), a, b)) = {(t, x) : |t− t0| ≤ a, |x− φ| ≤ b}, (2.4)
where a and b are two positive numbers. Recall that a function f : C → Rn is Lipschitz if
there exists a constant L > 0 such that
||f(x)− f(y)|| ≤ L||x− y||, (2.5)
for all x, y ∈ C. We will use the following theorem, taken from [35], to prove the existence
and uniqueness of a solution to our initial value problem formed by (2.1) with specified initial
conditions.
Theorem 2.1. (Modified from [35]) If the entries of f are real-valued and continuous on
a rectangular region R and if f satisfies the Lipschitz condition on R, then there exists a
unique solution to the initial value problem (2.3) for all t within a given distance of t0.
The next theorem (a simplified case of a theorem from [79]) specifies conditions on f which
ensure that non-negative initial conditions will guarantee non-negative solutions to (2.3).
Theorem 2.2. ([79]: Simpler case of Theorem 2.1, Chapter 5) Assume that when φ ∈ Rn
satisfies φ ≥ 0 with φi(0) = 0 for some i, then fi(φ) ≥ 0. Then, if φ ∈ Rn satisfies φ ≥ 0,
the solution of (2.3) satisfies x(t) ≥ 0 for all t ≥ t0.
We now use Theorem 2.2 to prove non-negativity of solutions to (2.1) with non-negative
initial conditions, assuming a solution exists, and Theorem 2.1 to prove the existence and
uniqueness of a solution to our system.
Theorem 2.3. For any vector of initial conditions φ = (R0, S0, C
−
0 , C
+
0 , D0, V0, (C
+
v )0) ≥ 0,
the system in (2.1) has a non-negative solution.
We check the hypotheses of Theorem 2.2.
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1. Assume φ = (0, S0, C
−
0 , C
+
0 , D0, V0, (C
+
v )0) ≥ 0. Then,
f1(φ) = ar(kS0 + kC
−
0 + kC
+
0 + kdD0 + kV0 + k(C
+
v )0) + θS0 ≥ 0.
2. Assume φ = (R0, 0, C
−
0 , C
+
0 , D0, V0, (C
+
v )0) ≥ 0. Then,
f2(φ) = as(krR0 + kC
−
0 + kC
+
0 + kdD0 + kV0 + k(C
+
v )0) + αR0 + pεD0 ≥ 0.
3. Assume φ = (R0, S0, 0, C
+
0 , D0, V0, (C
+
v )0) ≥ 0. Then,
f3(φ) = acn(krR0 + kS0 + kC
+
0 + kdD0 + kV0 + k(C
+
v )0)
+(1− f)S0(βcC+0 + βc(C+v )0 + βdD0) ≥ 0.
4. Assume φ = (R0, S0, C
−
0 , 0, D0, V0, (C
+
v )0) ≥ 0. Then,
f4(φ) = acp(krR0 + kS0 + kC
−
0 + kdD0 + kV0 + k(C
+
v )0)
+fS0(βcC
−
0 + βc(C
+
v )0 + βdD0) ≥ 0.
5. Assume φ = (R0, S0, C
−
0 , C
+
0 , 0, V0, (C
+
v )0) ≥ 0. Then,
f5(φ) = ad(krR0 + kS0 + kC
−
0 + kC
+
0 + kV0 + k(C
+
v )0) + φC
−
0 ≥ 0.
6. Assume φ = (R0, S0, C
−
0 , C
+
0 , D0, 0, (C
+
v )0) ≥ 0. Then,
f6(φ) = av(krR0 + kS0 + kC
−
0 + kC
+
0 + kD0 + k(C
+
v )0) + vS0 ≥ 0.
7. Assume φ = (R0, S0, C
−
0 , C
+
0 , D0, V0, 0) ≥ 0. Then,
f7(φ) = acv(krR0 + kS0 + kC
−
0 + kC
+
0 + kD0 + kV0) + v(C
−
0 + C
+
0 )
+V0(βcC
−
0 + βcC
+
0 + βdD0) ≥ 0.
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Therefore, whenever φ ≥ 0 (with φi(0) = 0 for some i), we have fi(φ) ≥ 0. By Theorem 2.2,
if a solution, X(t), to (2.1) exists for φ ≥ 0, the solution is non-negative for all t ≥ 0. 
Observe that
dR
dt
+
dS
dt
+
dC−
dt
+
dC+
dt
+
dD
dt
+
dV
dt
+
dC+v
dt
= 0.
This implies R(t)+S(t)+C−(t)+C+(t)+D(t)+V (t)+C+v (t) = c¯, for some constant c¯ ≥ 0.
If a solution to the system exists, then each component of the state solution must be less
than or equal to c¯ for all t ≥ t0, which (combined with the results of Theorem 2.3) means
0 ≤ R(t), S(t), C−(t), C+(t), D(t), V (t), C+v (t) ≤ c¯, (2.6)
for all t ≥ t0. Thus, if a solution exists, then our states are uniformly bounded.
Theorem 2.4. There exists a unique solution to the initial value problem formed by (2.1)
with specified initial conditions.
Proof : First, we denote X(t) = (R(t), S(t), C−(t), C+(t), D(t), V (t), C+v (t)) and define
dR
dt
= f1(X(t))
dS
dt
= f2(X(t))
dC−
dt
= f3(X(t))
dC+
dt
= f4(X(t)) (2.7)
dD
dt
= f5(X(t))
dV
dt
= f6(X(t))
dC+v
dt
= f7(X(t)),
with X(0) = X0 = (R0, S0, C
−
0 , C
+
0 , D0, V0, (C
+
v )0). Observe that the entries of f are all
real-valued and continuous. We now show f = (f1, f2, f3, f4, f5, f6, f7) is Lipschitz. We will
proceed by showing each component of f is Lipschitz. First, note that if a function of one
real variable has a bounded derivative, it is Lipschitz. If we can show that fi is Lipschitz in
each of its seven inputs, then fi is Lipschitz. To show each fi is Lipschitz with respect to
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a single input variable, we must show that the derivative of fi with respect to the i
th state
variable is bounded. In particular, to show f1 is Lipschitz, we must show its derivative with
respect to each input variable is bounded. The partial derivatives of f1 with respect to each
of the state variables are as follows:
∂f1
∂R
= arkr − (α + kr)
∂f1
∂S
= ark + θ
∂f1
∂C−
=
∂f1
∂C+
=
∂f1
∂V
=
∂f1
∂C+v
= ark
∂f1
∂D
= arkd.
For f3, we have
∂f3
∂R
= acnkr
∂f3
∂S
= acnk + (1− f)[βc(C+ + C− + C+v ) + βdD]
∂f3
∂C−
= acnk + (1− f)Sβc − (φ+ k + v)
∂f3
∂C+
= acnk + (1− f)Sβc
∂f3
∂D
= acnkd + (1− f)Sβd
∂f3
∂V
= acnk
∂f3
∂C+v
= acnk + (1− f)Sβc.
The resulting partial derivatives of fi with respect to each of the state variables for
i = 2, 4, 5, 6, and 7 are similar to the ones illustrated above in that they depend only on
products of parameter values and of parameter values with state variables. Thus, each partial
derivative is bounded. On compact subsets of C, each fi is Lipschitz in each of its inputs for
every i; thus, f is Lipschitz. Since the entries of f in (2.1) are real-valued and continuous
and since f is Lipschitz, by Theorem 2.1, there exists a unique solution to the initial value
problem formulated by (2.1) with specified initial conditions. 
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2.4 Optimal control of vaccination rate
We implement optimal control on the vaccination rate v to determine the time-varying,
optimal rate of vaccination over a particular time period because the cost-effectiveness of
a vaccine, in terms of both monetary and time resources, is so important. Our goal is
to minimize not only the overall impact of the disease but also the cost associated with
vaccination over a given period of time, [0, T ] for T > 0. The objective functional that
represents this goal is shown in (2.8).
J(v) := c0C
−(T ) +
∫ T
0
[
c1v(t)
(
S(t) + C−(t) + C+(t)
)
+ c2
(
v(t)
)2
+ c3D(t) + c4C
−(t) + c5λ(t)
(
S(t) + V (t)
)]
dt (2.8)
The first term in the objective functional, c0C
−(T ), counts the number of patients
asymptomatically colonized without protection at the final time and also ensures that
the value of the control is not forced to zero for some t ∈ [0, T ], as further explained
in Section 2.5.1. The next term, c1v(t)
(
S(t) + C−(t) + C+(t)
)
, represents the linear
cost associated with the vaccination process while c2
(
v(t)
)2
represents the nonlinear cost
that arises from difficulties faced when implementing a successful vaccination program.
The objective functional also accounts for the number of diseased patients with the term
c3D(t); by including this term, the disease prevalence in the population will be minimized.
Additionally, the objective functional includes terms for the number of C− patients, c4C−(t),
and for nosocomial disease transmission, c5λ(t)
(
S(t) + V (t)
)
. Recall the transmission rate
λ(t) = βc
(
C−(t) + C+(t) + C+v (t)
)
+ βdD(t). The coefficients ci ≥ 0, 0 ≤ i ≤ 5, represent
weights on the different terms of the objective functional. For some M > 0, the control set
is
V ∗ := {v : [0, T ]→ [0,M ] : v Lebesgue measurable}.
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The goal is to characterize the optimal control v∗ satisfying
inf
v∈V ∗
J(v) = J(v∗),
subject to the state system (2.1) with specified non-negative initial conditions for R, S, C−,
C+, D, V, and C+v . In order to use Pontryagin’s Maximum Principle (Theorem 1.1, [70]) to
characterize an optimal control, we must first prove that an optimal control exists.
2.4.1 Existence of optimal control
Theorem 2.5. There exists an optimal control v∗ that minimizes the objective functional
J(v) in (2.8) subject to the state system in (2.1) with specified non-negative initial conditions.
Proof. By (2.6) and Theorem 2.3, we know our state solutions are uniformly bounded for all
t ∈ [0, T ]. This, together with the boundedness of our control, implies that J(v) is bounded
below by 0, and, therefore, a minimum exists. Let {vn}∞n=1 be a minimizing sequence such
that
min
v∈V
J(v) = lim
n→∞
J(vn),
where Xn = (Rn, Sn, C
−
n , C
+
n , Dn, Vn, (C
+
v )n) are the state sequences corresponding to vn and
V = {v : [0, T ]→ [0,M ]|v Lebesgue measurable}.
The boundedness of the state sequences and control sequence imply that dRn
dt
, dSn
dt
, dC
−
n
dt
,
dC+n
dt
, dDn
dt
, dVn
dt
, d(C
+
v )n
dt
are each bounded for all t ∈ [0, T ]. Bounded derivatives imply Lipschitz
continuity; thus, each state sequence is Lipschitz continuous, and the state sequences are,
therefore, also equicontinuous. The Arzela-Ascoli Theorem states that every uniformly
bounded, equicontinuous sequence on a compact set has a uniformly convergent subsequence.
Therefore, each state sequence has a uniformly convergent subsequence:
Rnk → R∗ ∈ [0, N ], Snk → S∗ ∈ [0, N ], ..., (C+v )nk → (C+v )∗ ∈ [0, N ].
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Now, because |vn(t)| ≤ M for all n ∈ N and for all t ∈ [0, T ], we know vn ∈ L2(0, T ), and
for some constant C1 ≥ 0,
||vn||L2 ≤ C1, (2.9)
for all n ∈ N. As a consequence of the Banach-Alaoglu Theorem [25], every bounded sequence
in L2 has a weakly convergent subsequence; that is, there exists v∗ such that vnk ⇀ v
∗ in
L2. Using lower-semicontinuity of L2 norms with respect to weak convergence (see Theorem
4.10.7 in [25]), we have
||v∗||2(0,T ) ≤ lim inf
k→∞
||vnk ||2(0,T ). (2.10)
Let λnk = βc(C
−
nk
+ C+nk + C
+
vnk
) + βdDnk and λ
∗ = βc(C−
∗
+ C+
∗
+ C+
∗
v ) + βdD
∗. Note
that because J(vn) converges to min
v
J(v), any subsequence of J(vn) must converge to that
same limit. Additionally, because the state sequences and control sequence are L∞-bounded,
vnk ⇀ v
∗ in L2, and the state subsequences converge uniformly in L2,
∫ T
0
vnk
(
Snk + C
−
nk
+ C+nk
)
dt→
∫ T
0
v∗(S∗ + C−∗ + C+∗)dt.
We then have the following:
min
v
J(v) = lim
n→∞
J(vn) = lim
k→∞
J(vnk)
= lim inf
k→∞
J(vnk)
≥ lim inf
k→∞
∫ T
0
[
c1vnk(Snk + C
−
nk
+ C+nk) + c3Dnk + c4C
−
nk
+ c5λnk (Snk + Vnk)
]
dt
+ lim inf
k→∞
c0C
−
nk
(T ) + lim inf
k→∞
c2||vnk ||22(0,T )
≥
∫ T
0
[
c1v
∗(S∗ + C−∗ + C+∗) + c3D∗ + c4C−∗ + c5λ∗ (S∗ + V ∗)
]
dt
+c0C
−∗(T ) + ||v∗||22(0,T )
= J(v∗).
Thus, min
v
J(v) = J(v∗), so v∗ is optimal. 
22
2.4.2 Characterization of optimal control
Now that we have established existence, we can apply Pontryagin’s Maximum Principle
(Theorem 1.1, [70]) to derive necessary conditions on the optimal control.
Theorem 2.6. Given an optimal control v∗ and solutions to the corresponding state system
in (2.1), there exist adjoint variables λi, i = 1, ..., 7, satisfying
λ′1 = −λ1(arkr − α− kr)− λ2(askr + α)− kr(λ3acn + λ4acp + λ5ad)
−kr(λ6av + λ7acv)
λ′2 = −c1v − c5λ− λ1(kar + θ)− λ2(ask − θ − k − λ− v)
−λ3[acnk + (1− f)λ]− λ4(acpk + fλ)− λ5adk
−λ6(kav + v)− λ7acvk
λ′3 = −c1v − c4 − c5βc(S + V )− λ1ark − λ2(kas − βcS)
−λ3[acnk + (1− f)βcS − φ− k − v]− λ4(fβcS + kacp)
−λ5(kad + φ)− λ6(kav − βcV )− λ7(βcV + kacv + v)
λ′4 = −c1v − c5βc(S + V )− λ1ark − λ2(kas − βcS)− λ3[acnk + (1− f)βcS]
−λ4(fβcS + kacp − k − v)− λ5adk − λ6(kav − βcV ) (2.11)
−λ7(βcV + kacv + v)
λ′5 = −c3 − c5βd(S + V )− λ1arkd − λ2(pε− βdS + askd)
−λ3[acnkd + (1− f)βdS]− λ4(fβdS + acpkd)− λ5(adkd − pε− kd)
−λ6(avkd − βdV )− λ7(βdV + acvkd)
λ′6 = −c5λ− λ1ark − λ2kas − λ3acnk − λ4acpk − λ5adk
−λ6(avk − k − λ)− λ7(acvk + λ)
λ′7 = −c5βc(S + V )− λ1ark − λ2(kas − βcS)− λ3[acnk + (1− f)βcS]
−λ4(fβcS + kacp)− λ5adk − λ6(kav − βcV )− λ7(βcV + kacv − k),
λi(T ) = 0, for i 6= 3
λ3(T ) = c0.
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Furthermore, v∗ is represented as
v∗ = min{M,max{0, vˆ}}, (2.12)
where
vˆ =
λ2S + λ3C
− + λ4C+ − λ6S − λ7(C+ + C−)− c1(S + C+ + C−)
2c2
. (2.13)
Proof. The Hamiltonian is given by
H = c1v(S + C
− + C+) + c2v2 + c3D + c4C− + c5(S + V )λ
+λ1
dR
dt
+ λ2
dS
dt
+ λ3
dC−
dt
+ λ4
dC+
dt
+ λ5
dD
dt
+ λ6
dV
dt
+ λ7
dC+v
dt
.
Pontryagin’s Maximum Principle (Theorem 1.1, [70]) gives the existence of adjoint variables
satisfying the system in (2.11) using
λ′1 = −
∂H
∂R
, λ′2 = −
∂H
∂S
, λ′3 = −
∂H
∂C−
, λ′4 = −
∂H
∂C+
, λ′5 = −
∂H
∂D
,
λ′6 = −
∂H
∂V
, and λ′7 = −
∂H
∂C+v
,
with transversality conditions λi(T ) = 0 for i 6= 3 and λ3(T ) = c0. We then have
∂H
∂v
= c1(S + C
− + C+) + 2c2v − λ2S − λ3C− − λ4C+ + λ6S + λ7(C− + C+).
On the interior of the control set, ∂H
∂v
∣∣
v∗ = 0. Thus, we can solve for the optimal control on
the interior:
v∗(t) =
λ2S + λ3C
− + λ4C+ − λ6S − λ7(C+ + C−)− c1(S + C+ + C−)
2c2
.
Note that on {t|v∗(t) = 0}, ∂H
∂v
≥ 0 and on {t|v∗(t) = M}, ∂H
∂v
≤ 0. Combining all three cases
leads to the characterization of our optimal control given in (2.12).
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2.5 Numerical results
The optimality system, which consists of the state system in (2.1) with initial conditions,
adjoint system in (2.11) with transversality conditions, and characterization of the optimal
control in (2.12), is solved using a Forward-Backward Sweep method [33, 49]. This is an
iterative method that solves the system using a fourth-order Runge-Kutta (RK4) scheme.
We start with an initial guess for our control value and then use RK4 and the given initial
conditions to solve the state system in (2.1) forward in time. Then, we use the initial control
guess, the transversality conditions given for our adjoints, and the values for the state system
solution to solve the adjoint system in (2.11) backward in time. Next, our control value v is
updated by entering the new state and adjoint values into the characterization of the control
in (2.12). Finally, convergence is checked, and the process is repeated until values converge
sufficiently.
Unless otherwise stated, M = 0.3 per day so that 0 ≤ v(t) ≤ 0.3 as discussed at the end
of Section 2.2. Additionally, we set T = 30 so that we are considering 30-day intervals. Short
periods of time are considered because the hospital will change states, thereby potentially
shifting some parameter values, and the vaccination strategy will need to be reevaluated
after the 30 days and possibly modified in response to this shift.
2.5.1 Summary of exploration into weighting coefficient values
Before any results were determined, we first gained an understanding of how changing the
values of our weighting coefficients, ci, affected the optimal control, v
∗. Because vaccination
against CDI is still in testing, we do not have data that details the cost associated with
such a program. Once this data is known, it can be incorporated into the appropriate
weighting coefficient values. For now, to establish how a particular weighting coefficient
changes the optimal vaccination rate, we varied the value for one weighting coefficient while
keeping all other coefficients fixed, some at 0. Additionally, we compared the relative size
of each term, without being multiplied by the corresponding weighting coefficient, in the
objective functional J(v) given in (2.8). In particular, we observed that the nonlinear cost
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associated with vaccination, given as v2, and the transmission, λ(S + V ), are relatively
small in comparison to the other terms. Therefore, we allow their corresponding weighting
coefficients, c2 and c5, to be relatively large in comparison to the remaining coefficients.
After considering various scenarios in which we varied one weighting coefficient value
while keeping the others fixed, we made several conclusions. First, we concluded that if
control cost coefficient c1 exceeds some threshold value, then v
∗(t) = 0 for all t ∈ [0, T ].
Since we do not want to consider a case in which vaccination is too costly to implement at
all, we keep c1 relatively small. Note that because the nonlinear cost term is smaller than
the linear cost term in the objective functional, increasing c2 does not force v
∗ to be 0 for
the entire time period in the way that increasing c1 does.
Next, note that if c0, the weighting coefficient on the final time condition, is 0, the optimal
vaccination rate will always drop down to 0 at some point in our time period no matter what
the values are for the remaining weighting coefficients. In fact, there exists some threshold
value cˆ0 such that for c0 < cˆ0, v
∗(t) = 0 for t ∈ [tˆ, T ], for some tˆ ∈ [0, T ]. This is because
if c0 = 0, then λi(T ) = 0 for i = 1, ..., 7, which means vˆ, in (2.13), is negative at the final
time, and by the characterization of the optimal control in (2.12), this implies v∗(T ) = 0. It
is not practical to have to drop down to a vaccination rate of 0 in every scenario; therefore,
we considered values for c0 large enough to prevent this forced decrease to 0. Finally, note
that an increase in c3 or c4 adds emphasis to our desire to minimize the overall impact of the
disease and thereby leads to an increased v∗. The last term in J(v), c5λ(S + V ), involves a
bit of a balancing act. We want to increase the number of vaccinated patients V while also
minimizing this term as part of the objective functional. Thus, depending on the value of
V , increasing c5 may decrease v
∗ or increase v∗.
The exploration of values summarized in this section provided us with an idea of how to
set weighting coefficient values in the simulations to come. The weighting coefficient values
chosen are as follows: c0 = 3, c1 = 0.1, c2 = c5 = 15, and c3 = c4 = 0.5, and the resulting v
∗
obtained using this combination of weighting coefficients is shown in Figure 2.2.
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Figure 2.2: Optimal vaccination rate v∗ for c0 = 3, c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5,
M = 0.3, and T = 30
2.5.2 Determining the impact of vaccination
In this section, we compare the population behavior with no vaccination to its behavior with
vaccination implemented using optimal control and observe the differences. In Figure 2.3,
the optimal states that correspond to the time-varying optimal vaccination rate v∗ illustrated
in Figure 2.2 are plotted alongside the states corresponding to no vaccination. We see from
Figure 2.3 that without vaccination, each of the classes reaches its steady state before the
30 days have expired. Furthermore, Figure 2.3 illustrates that this particular vaccination
rate v∗ decreases the number of patients in C− by approximately 4 in 30 days and the
number of patients in D by approximately 2. Figure 2.3 also shows that the total number
of colonized patients remains approximately the same (a difference of less than 1 person)
when this optimal time-varying vaccination rate is implemented. Additionally, vaccination
also leaves the hospital with a significantly lower number of patients who are susceptible to
becoming colonized (approximately 47 fewer), which is significant since C. difficile spores
can survive for extended time periods on various hospital surfaces.
Because the restriction of M = 0.3 per day is not a strict one, we also considered an
increased upper bound on v. Figures 2.4(a) and 2.4(b) compare the optimal vaccination rate
v∗ for M = 0.3 per day to that in the increased case of M = 0.6 per day with the same
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Figure 2.3: Dynamics of patient transition states with optimal vaccination rate v∗ shown
in Figure 2.2 compared to those without vaccination for c0 = 3, c1 = 0.1, c2 = c5 = 15,
c3 = c4 = 0.5, M = 0.3, and T = 30
weighting coefficient values previously considered. Observe from Figure 2.4(a) that for this
case, an increase in M only initially alters v∗. Figure 2.4(b) zooms in on this initial change
in v∗ by displaying an interval of only 3 days. Additionally, note that the v∗ obtained for
M = 0.6 produces the exact same corresponding state populations for all 30 days that the
v∗ with M = 0.3 produces (results not shown).
To determine the impact of using a time-varying vaccination rate, we compare the value of
the objective functional, J(v) in (2.8), obtained with our time-varying optimal vaccination
rate to that obtained with a constant vaccination rate of 0.3 per day for the entire time
period. For the particular case of weighting coefficient values illustrated in Figures 2.2 and
2.3 and for the case with an increased upper bound (shown in Figure 2.4), various J(v) values
are compared in Table 2.5. First, observe that whether M = 0.3 or M = 0.6, a time-varying
optimal vaccination rate engenders a savings over a constant rate. Furthermore, if M is
increased to 0.6 per day, then a time-varying vaccination rate leads to a much more notable
savings over the case of a constant rate than the M = 0.3 case does. Thus, if we allow for
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Figure 2.4: (a) Comparison of optimal vaccination rate v∗ with upper bound M = 0.3 to
that with the increased value of M = 0.6 with c0 = 3, c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5,
and T = 30 (b) View of (a) over a 3-day interval to observe the initial difference in v∗
Table 2.5: Comparison of J(v) with constant vaccination rate to J(v) with time-varying
optimal vaccination rate, shown in Figure 2.4, for various upper bounds, M , on v(t)
M J(v) with constant v(t) = M J(v) with time-varying optimal v∗
0.3 203 192
0.6 305 192
an increased upper bound on the vaccination rate, then we see a more stark difference and
impact of time-varying vaccination versus that of constant vaccination.
2.5.3 An increase in susceptible patients
In this section, we explore the question of how hospitals should modify their vaccination
strategy in order to handle a larger number of susceptible patients. To do this, we consider
alternate hospital statuses in which an increased number of patients have either received
antibiotics after admission or taken them prior to admission.
First, if a particular hospital is prescribing high-risk antibiotics at an increased rate, this
corresponds to an increase in α and thereby also an increase in the number of susceptible
patients since more patients will have an altered intestinal microbiota. Assessing the effect of
varying α on the resulting optimal control is also an interesting scenario because we showed
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Table 2.6: Comparison of J(v) and total vaccinated with constant vaccination rate to J(v)
and total vaccinated with time-varying optimal vaccination rate, shown in Figure 2.5, for
various antibiotic prescription rates, α
α
J(v) with
constant
v(t) = 0.3
J(v) with
time-varying
optimal v∗
Total vaccinated
with constant
v(t) = 0.3
Total vaccinated
with
time-varying
optimal v∗
0.5 203 192 405 319
1 201 187 447 332
5 199 181 493 338
that our objective functional, (2.8), was particularly sensitive to α (see Appendix A). For
all simulations thus far, α = 0.5 per day as listed in Table 2.3. Figure 2.5 illustrates how
v∗ changes for increasing α. Note that as α is increased, v∗ decreases. To understand this
downward shift, we first compare the patient population dynamics for the various α values,
shown in Figure 2.6. From this, we see that when α is increased, we are able to reduce C−
and D to approximately the same number seen for the lower α-value of 0.5, but we do so
with a lower v∗ and therefore also a lower value of J . Additionally, with the higher antibiotic
prescription rate, we observe that the total colonized population is also decreased.
Note that the number of susceptible patients vaccinated per day is given by vS. Since S
is increased in this scenario, v∗ can correspondingly decrease to lead to the same, or even
a slightly increased, number of susceptible patients being vaccinated per day. Essentially,
because there is an increased number of susceptible patients available to vaccinate due to the
increase in α, we are able to vaccinate more patients (even at a lower rate). This increase
in V engenders the decrease in the number of C− and D patients. From Table 2.6, observe
that we vaccinate more patients as α is increased whether we use a constant vaccination
rate or a time-varying one. Furthermore, Table 2.6 also indicates that time-varying rates of
vaccination in this scenario may be more economical than constant rates.
Another way for a hospital to experience an increase in susceptible patients is to have
more upon admission due to a greater number of patients taking antibiotics before entering
the hospital. We considered this case by increasing the proportion of susceptible patients
admitted, as, and thereby also increasing the initial number of susceptible patients by
adjusting the remaining admission proportions and initial conditions to reflect the change.
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Figure 2.5: Optimal vaccination rate v∗ for increasing antibiotic prescription rate, α, and
for c0 = 3, c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5, M = 0.3, and T = 30
Days
0 5 10 15 20 25 30
R
0
50
100
150
Days
0 5 10 15 20 25 30
S
0
50
100
150
Days
0 5 10 15 20 25 30
C
-
4
6
8
10
Days
0 5 10 15 20 25 30
C
-
+
C
+
+
C
v+
20
22
24
26
Days
0 5 10 15 20 25 30
D
2
2.5
3
3.5
4
Days
0 5 10 15 20 25 30
V+
C v+
0
20
40
60
80
α=0.5
α=1
α=5
Figure 2.6: Dynamics of patient transition states for increasing antibiotic prescription rate,
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Table 2.7: Comparison of J(v) with constant vaccination rate to J(v) with time-varying
optimal vaccination rate, shown in Figure 2.7, for various transmission coefficients, βc and
βd
βc, βd J(v) with constant v(t) = 0.3 J(v) with time-varying optimal v
∗
10−6 203 192
0.0007 1,224 1,216
0.007 6,416 6,416
This scenario produced results that were similar to those obtained when increasing α and
are omitted here.
2.5.4 Increasing transmission coefficients
Another scenario we considered is the case of an outbreak, meaning an increase in the
transmission coefficients, βc and βd. Such an increase in transmission coefficients could occur
for a multitude of reasons, one of which being an understaffed hospital in which workers may
not be following proper protocol such as adequate washing of hands and wearing of gloves
when necessary. Additionally, note that the system in [45] was found to be particularly
sensitive to βc and our objective functional, (2.8), was found to be sensitive to βc and βd (see
Appendix A), so we determined the case of changing βc and βd was one worth exploring.
Recall that thus far βc = βd = 10
−6.
Figure 2.7 shows how such an increase in βc and βd affects the optimal vaccination rate.
As expected, in such a scenario, we should increase the vaccination rate in order to contain
the outbreak. As βc and βd are increased, a time-varying optimal vaccination rate is just
barely more cost-effective than a constant vaccination rate since v∗ is increased closer to its
maximum allowed rate of 0.3 per day. The savings in J(v) are decreased as βc and βd are
increased, as shown in Table 2.7. In a particularly bad outbreak, the optimal vaccination
rate is constant at the upper bound of M = 0.3, as shown in Figure 2.7 for βc, βd = 0.007.
The resulting patient state dynamics for each set of transmission coefficient values
considered in Figure 2.7 are illustrated in Figure 2.8. For the increased transmission
coefficient values of βc, βd = 0.007, a comparison of the state dynamics with no vaccination
to those with vaccination implemented using optimal control is shown in Figure 2.9. In this
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Figure 2.7: Optimal vaccination rate v∗ for increasing transmission coefficients, βc, βd, and
for c0 = 3, c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5, M = 0.3, and T = 30
case, observe that vaccination has a much more significant impact than the scenario shown
in Figure 2.2, and in 30 days decreases the number of C− patients by approximately 20 and
the number of D patients by approximately 10.
We also considered scenarios in which we increased the clinical disease rate φ while
simultaneously increasing the transmission coefficients βc and βd. Note that in this case,
the trend remains essentially the same to that when only βc and βd are increased. The
only difference is that there is an increase in D when φ is also increased, which is expected.
Because the results were similar, they are omitted.
Note that an increase in the upper bound M on the vaccination rate may be reasonable
for some hospitals depending on a combination of factors. One such factor is how many
people a hospital can manage to vaccinate in a day. If staff increases its efforts, the hospital
may be able to handle an increase in vaccination rate. Additionally, if it becomes easier to
convince persons to be vaccinated, such a scenario would also call for an increase in M . Since
the most extreme outbreak, with βc, βd = 0.007, forces v
∗ to become constant at its upper
bound, we also wanted to explore how v∗ would change with an increase in the upper bound
M to 0.6. The resulting v∗ is illustrated in Figure 2.10 alongside v∗ with M = 0.3. The
corresponding state trajectories are given in Figure 2.11 for M = 0.3 and 0.6. This figure
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Figure 2.9: Dynamics of patient transition states with vaccination rate shown in Figure 2.7
for the increased values of βc, βd = 0.007 compared to those without vaccination for c0 = 3,
c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5, M = 0.3, and T = 30
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Figure 2.10: Optimal vaccination rate v∗ for increasing M with increased βc, βd = 0.007,
c0 = 3, c1 = 0.1, c2 = c5 = 15, c3 = c4 = 0.5, and T = 30
Table 2.8: Comparison of J(v) with constant vaccination rate to J(v) with time-varying
optimal vaccination rate, shown in Figure 2.10, for various upper bounds, M , on v(t) with
increased βc, βd = 0.007
M J(v) with constant v(t) = M J(v) with time-varying optimal v∗
0.3 6,416 6,416
0.6 6,433 6,398
shows that D and C− are decreased more in the case when M = 0.6 than when M = 0.3.
Furthermore, from Table 2.8, observe that in the case of the increased upper bound, there
is a notable benefit to using time-varying control over a constant rate of vaccination for all
30 days. Notably, the value of J(v) for the optimal v∗ corresponding to M = 0.6 is smaller
than the value of J(v) for the optimal v∗ corresponding to M = 0.3. Thus, allowing for an
increase in the upper bound on v(t) could lead to an overall savings and a greater impact on
reducing disease prevalence and incidence. We conclude that time-varying vaccination could
be beneficial in more extreme outbreak scenarios (i.e., βc, βd = 0.007) with this upper bound
increase, whereas without this increase, a constant rate of vaccination would be preferred.
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Figure 2.11: Dynamics of patient transition states with optimal vaccination rates shown
in Figure 2.10 with various upper bounds M for the increased values of βc, βd = 0.007 for
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2.6 Discussion
The recent striking growth in the prevalence of Clostridium difficile infection (CDI) in
healthcare facilities highlights the need for finding effective strategies for prevention. A new
potential prevention strategy is being considered as two international studies are underway
to test the effectiveness of a vaccine against the toxins produced by C. difficile [48]. In
anticipation of this vaccine, we have extended and updated a mathematical model of C.
difficile transmission in hospitals to include vaccination. We then employed optimal control
theory in order to find the time-varying optimal rate at which hospitals should vaccinate
patients that minimizes disease prevalence and transmission while also minimizing the cost
associated with vaccination.
In this chapter, our simulations considered 30-day time periods since vaccination
strategies will need to be reevaluated after this due to parameter values that may change
during this period. We considered different hospital statuses and compared time-varying
rates to constant rates in order to determine in which scenarios a time-varying rate would
be preferred. First, we considered a scenario in which hospitals have an increased number
of susceptible patients due to more high-risk antibiotics being given either prior to or after
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admission. We saw that with this increase in the number of susceptible patients, the optimal
vaccination rate decreased. In this scenario, hospitals could reduce all colonized populations
(asymptomatic and symptomatic) by the same amount (or slightly more), with a lower
vaccination rate and lower objective functional value. This is because there are more patients
available to be vaccinated in this scenario. In this case, a time-varying rate of vaccination
was shown to be more beneficial.
Another situation that hospitals commonly experience is that of an outbreak. In this
scenario, we saw that an increase in transmission coefficients led to a simultaneous increase in
the optimal vaccination rate. Because part of our main goal is to minimize disease prevalence
and transmission, as C. difficile spores are being transmitted at a higher rate, we must
vaccinate more to control this outbreak. Once the transmission coefficients increased to
some threshold value, the optimal vaccination rate became constant at its upper bound.
Therefore, in more severe outbreaks a constant vaccination rate is optimal to accomplish our
goal rather than a time-varying one, unless we allow for an increase in the upper bound on
the vaccination rate.
It is important to note that the upper bound of 0.3 we imposed on the vaccination
rate is not a strict upper bound. For this reason, we also considered how an increased upper
bound changed our results. In particular, we observed that in some cases of severe outbreak a
time-varying optimal vaccination rate is more economical when the upper bound is increased.
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Chapter 3
Agent-based model of nosocomial C.
difficile transmission
3.1 Introduction
Since the early 2000s, a notable increase in the incidence and severity of CDI has placed a
substantial burden on healthcare facilities [41, 40, 84]. In particular, the North American
population has experienced a fivefold increase in CDI incidence with an eightfold increase in
the elderly [68], and the cost associated with CDI in United States acute-care facilities alone
has been estimated to be as much as $4.8 billion annually [20]. These increases are due, in
part, to significant changes in the epidemiology of C. difficile with the emergence of a new
hypervirulent strain [40]. Thus, there is a critical need to better identify primary sources of
transmission in order to determine optimal methods for prevention.
Mathematical and computational models provide a mechanism for evaluating the complex
interactions driving transmission and for making recommendations about disease control and
surveillance. Models using differential equations have previously been developed to represent
nosocomial transmission [6, 86, 45, 36, 88, 81]. Using a compartmental model of C. difficile
transmission in a healthcare setting, Lanzas et al. [45] concluded that asymptomatic patients
are significant contributors to within-ward transmission. Increased awareness of the role of
environmental transmission in the spread of some pathogens has led to the development
of models that incorporate environmental components [38, 83, 74]. Updated studies have
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indicated that the primary reservoirs of CDI are both colonized individuals (asymptomatic
and symptomatic) and contaminated environments [39, 8, 75]. Because of this, we aim to
expand our modeling assumptions to explicitly include the additional transmission pathway
of environmental contamination.
Evidence has linked the acquisition of nosocomial pathogens to their presence on hospital
surfaces, and C. difficile, in particular, has been found on beds, sinks, toilets, walls, rails,
call buttons, and stretchers [28]. C. difficile spores can survive for extended periods of
time, even years, on these hospital surfaces and are resistant to drying, heat, exposure to
air, and most disinfectants and detergents [28]. Because the persistence time of C. difficile
in the environment is often longer than the duration of pathogen shedding by infectious
individuals, the risk of a susceptible individual becoming colonized greatly depends on the
level of pathogen in the surrounding environment [18]. The survival of C. difficile spores
on hospital surfaces makes healthcare workers (HCWs) important vectors of transmission,
particularly if they exhibit poor hand-hygiene practices [28].
Antibiotic use has been shown to be the primary risk factor for contracting CDI since
antibiotics disrupt the normal gut microbiota [63], allowing C. difficile to proliferate and
colonize [3]. Certain antibiotics may make individuals more susceptible to colonization by
C. difficile than others. This depends on the spectrum, duration, and number of antibiotics
received [78, 14, 5]. Prolonged duration of antibiotic use and use of multiple antimicrobial
agents are both linked to increased risk of contracting CDI [40]. Broad-spectrum antibiotics,
such as amoxicillin, work against a broad range of bacteria, which results in more significant
gut microbiota disturbance and, thereby, an increased risk for C. difficile colonization [67].
Strategies have been implemented to reduce the transmission of C. difficile in healthcare
environments. Such strategies include antimicrobial usage restriction and stewardship,
isolation of patients with CDI, environmental decontamination of rooms with bleach, and
improved HCW hand-hygiene and contact protocol [18]. Antimicrobial stewardship involves
an overall reduction in the number of antibiotics prescribed and/or a reduction targeted
specifically at the proportion of antibiotics prescribed that are associated with a higher
chance of contracting CDI, such as broad-spectrum antibiotics [23, 82, 5]. Current hospital
practice calls for the identification and subsequent isolation of patients with CDI so that
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proper contact precautions can be implemented to decrease the chances of pathogen spread
[18]. Assessments of hospital cleaning practices have shown that routine disinfection is
often not performed efficiently and as a result, it is ineffective at eradicating nosocomial
pathogens [28]. Therefore, more purposeful cleaning with bleach can be an important
strategy for reducing the pathogen level in a healthcare setting [29]. HCWs’ hands can
become contaminated after touching surfaces with C. difficile spores [60, 17], and studies
have shown that adherence to best hand-hygiene and contact protocol practices have been
difficult to maintain [64, 10]. Because the spread of nosocomial pathogens has been linked
to poor hand-hygiene practices [28], improved adherence of HCWs to proper hand-washing
and contact protocols is also an important control measure. Vaccination may soon be an
addition to the current control strategies since early results of clinical trials of a C. difficile
toxoid vaccine show efficacy in preventing CDI [84]. Although this vaccine does not prevent
colonization by C. difficile, it may be effective for reducing transmission in hospital settings.
Studies have been completed to determine the individual impact of these control measures
on the spread of C. difficile [55, 31, 66, 21], and several computational models [75, 10, 13, 5]
have been designed to determine the optimal combination of intervention strategies for
reducing C. difficile transmission. Agent-based and individual-based models allow us to
define a system based on individual behaviors and interactions. These individual behaviors
are simulated to observe emergent behaviors of the entire system [72]. Agent-based
models (ABMs) also allow us to incorporate spatial heterogeneity, consider a variety of
transmission pathways, and incorporate individual patient characteristics that are significant
in determining transmission. ABMs also inherently have stochastic components that can
result in different outcomes from similar starting conditions.
D’Agata et al. [13] used an individual-based model to determine the key contributing
factors to nosocomial transmission of a general antimicrobial-resistant bacteria. Their
model focused on the admission and exit of patients, infection of patients by HCWs, and
contamination of HCWs by patients; however, their study did not include an environmental
reservoir. They also analyzed the role of antibiotics, including the duration of treatment and
the scheduling of treatment initiation. One drawback of considering a general antimicrobial-
resistant bacteria is the inability to incorporate characteristics specific to a single type of
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bacteria. By only monitoring one individual patient characteristic (the bacterial load during
antibiotic treatment), this model ignores other individual patient characteristics that are
especially relevant to CDI incidence, such as disease status at admission. In particular,
patients colonized at admission significantly contribute to C. difficile transmission [12], so
tracking patient disease status at admission is important when modeling CDI transmission.
The ABM created by Codella et al. [10] specifically considered C. difficile and included
patients, HCWs, and visitors. The agents were able to interact with each other and the
environment as possible sources of transmission. Neither this model nor the one created by
D’Agata et al. [13] considered within-hospital patient history, such as the level of risk of C.
difficile colonization associated with the particular antibiotics prescribed. Additionally, it is
important to track when antibiotic treatment began since both the spectrum and duration
of antimicrobial treatment affect the probability of a susceptible patient becoming colonized.
The ABM of C. difficile transmission developed by Rubin et al. [75] does group antibiotics
into classes based on the level of risk; however, none of the three ABMs mentioned evaluated
antimicrobial stewardship as a control measure. This is notable because antimicrobial
stewardship has been linked with the greatest evidence for preventing CDI in healthcare
environments [37].
The ABM of C. difficile transmission created by Bintz et al. [5] focused on evaluating the
efficacy of various control measures aimed at “reducing environmental contamination and
mitigating the effects of antibiotic use on transmission” of C. difficile in order to reduce
colonization and infection incidence within the hospital. Their model accounts for the
heterogeneity of the environment and of the antibiotics prescribed. They denote various
risk levels for antibiotics, according to the degree of microbiota disturbance they cause,
and, consequently, the likelihood of colonization by C. difficile. By accounting for both the
type and number of antibiotics each patient receives while in the hospital, they were able
to simulate antimicrobial stewardship programs. In addition to considering antimicrobial
stewardship as a control measure, they also considered environmental decontamination
strategies. They tracked many individual patient characteristics that are relevant for
determining the probability of colonization, such as disease status at admission, risk level
of the antibiotic received, and the local contamination level. A major assumption of their
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model is that the impact of HCWs on transmission can be estimated without explicitly
incorporating HCWs as agents in the model. Bintz et al. [5] implicitly incorporate the impact
of HCWs by considering ward-level contamination in addition to room-level contamination,
but they do not consider HCWs as agents.
In this study, we develop an ABM of the spread of C. difficile in healthcare environments
that includes environmental transmission and explicitly includes HCWs as vectors of
transmission. The goal of our work is to build on the ideas formulated by Bintz et al. [5]
in order to create an ABM of C. difficile transmission that incorporates specific patient
histories, antibiotic histories, and antibiotic risk levels and that explicitly incorporates
HCWs as agents. Using this model, we aim to evaluate various control strategies, such as
environmental cleaning, antimicrobial stewardship, improved HCW hand-hygiene practices,
and vaccination in order to determine the optimal combination of strategies for reducing
nosocomial C. difficile colonization and infection incidence. Specifically, we hope to answer
questions that the previous model [5] with only implicit HCWs was unable to answer, such
as the effectiveness of improved HCW hand-hygiene practices as a control intervention. It
is worth noting that none of the ABMs previously mentioned considered vaccination as a
control measure. With positive early results of C. difficile toxoid vaccine trials [84], we
saw benefit in performing a preliminary assessment of vaccination both individually as an
intervention strategy and coupled with other interventions.
In Section 3.2, we give an overview of the structure of and components in our ABM,
including a description of patient-HCW-environment interactions and specific characteristics
tracked for HCWs, patients, and rooms. In Section 3.3, we discuss the control interventions
and the combinations of interventions that we evaluated. Section 3.4 describes the
computational methods we used to obtain our results, and Section 3.5 summarizes the results
of our simulations and intervention comparisons. A discussion of implications and conclusions
follows in Section 3.6. Specific details about the model structure and implementation are
described using the standard Overview, Design Concepts, and Details (ODD) protocol [72]
in Section 3.7.
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3.2 Model overview
In this section, we give an overview of the structure of and components in our ABM of
nosocomial C. diffcile transmission. For all the specific details about model design and
implementation in their entirety, see the ODD protocol in Section 3.7 and the descriptions of
the submodels in Section 3.8. Our ODD protocol follows the standard formatting originally
developed by Grimm, Railsback, and their collaborators [32].
3.2.1 Model setting
We developed our ABM using NetLogo, a coding language primarily used for the creation of
ABMs. Our model is a modification and extension of the ABM originally created by Bintz
et al. [5]. The model environment is a hospital consisting of six wards, each with 35 patient
rooms. A snapshot of the graphical user interface of our model environment in NetLogo is
shown in Figure 3.1. We assume these are all single-patient rooms, so there can be at most
210 patients in the hospital at a time. For simplicity and to ensure we never have more
patients than available rooms, we maintain a constant occupancy level. That is, the number
of new patients admitted at a given time always equals the number of patients discharged at
the previous time. The number of HCWs in the hospital is chosen to maintain a 3:1 ratio of
patients to HCWs, and each time an HCW leaves the hospital, a new one arrives to maintain
a constant total population of HCWs.
The model has two types of agents: patients and HCWs, and the environmental patches
represent ward rooms. We track behaviors and characteristics specific to each individual
agent and each individual patch. The individual characteristics and interactions can give rise
to interesting overall population dynamics, and the resulting outputs of model simulations
will vary based on the individual behaviors. Patient interactions and characteristics are
updated at every half-day time-step, which mimics the time-scale of the ABM in [5], while
HCW interactions and characteristics are updated at every 15-minute time-step. Many of
the values for the parameters used in the model were taken from a dataset originally used
in [45] that was collected from Barnes-Jewish Hospital in St. Louis, Missouri.
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Figure 3.1: Snapshot of the graphical user interface of our model environment in NetLogo
as a hospital with six wards that each have 35 rooms, where the dice represent patients,
the people represent HCWs, and the colors represent the amount of contamination in that
room (yellow indicates low contamination, green is medium contamination, and brown is
high contamination)
3.2.2 Model components
For each ward room, we track its contamination level over time. The more surfaces in a room
contaminated by C. difficile spores, the higher the room’s contamination level. Pathogen
shedding of both symptomatic and asymptomatic patients will increase the contamination
level of a room. However, we assume that the shedding of symptomatic patients contributes
more to room contamination than that of asymptomatic carriers since it has been shown that
those with CDI shed more C. difficile in their stool [18], which leads to more environmental
contamination. Patients who are not colonized by C. difficile will have no effect on the
contamination level of the room in which they are residing.
For all patients, we assign a length of stay in the hospital based on their disease status
upon admission and on data for the lengths of stays of patients at Barnes-Jewish Hospital
[45, 5]. We also track each patient’s time since admission, and once the time since admission
reaches the preassigned length of stay, that patient is discharged from the hospital.
All patients, regardless of their disease status with respect to C. difficile, have a
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probability of receiving an antibiotic (for treating illnesses not related to C. difficile) at
each half-day time-step. Because different types of antibiotics result in varying degrees of
microbiota disturbance and, therefore, varying risks of colonization by C. difficile [78, 14],
we group antibiotics into three risk levels with respect to C. difficile: low-, high-, and very
high-risk [5]. The risk level of an antibiotic directly affects the time until restoration of a
normal gut microbiota and a patient’s incubation period (the time between exposure to C.
difficile and the onset of symptoms). In particular, higher risk antibiotics are associated
with shorter incubation periods and longer periods until successful restoration of the gut
microbiota. The model tracks the associated risk level of each antibiotic a patient receives
and the number of antibiotics each patient receives while in the hospital. Additionally, the
amount of time each patient spends on a particular antimicrobial therapy is tracked. Because
of this, we are able to incorporate the impact of the antibiotic type, duration of treatment,
and number of antibiotics on the risk of colonization and subsequent infection by C. difficile.
Throughout a patient’s stay, we track the progression of his or her disease status, and
we begin by noting the patient’s disease status at admission. There are four possible disease
statuses of patients: resistant, susceptible, (asymptomatically) colonized, and diseased.
Upon admission, a patient’s disease status is determined based on the admission proportions
for each disease class. We use the same admission proportions here as we used in our ODE
model in Chapter 2, in which the proportions were based on hospital data with modifications
made to the colonized admission proportion because of updated data given by Alasmari et
al. [1].
All possible transitions among disease states are represented in Figure 3.2. Because
antibiotic use is widely recognized as the most significant risk factor for colonization by
C. difficile [48, 40], we make the same assumption here that we made in our ODE model
(Chapter 2): a patient only becomes susceptible to colonization after beginning antimicrobial
therapy. Those who have not recently undergone antimicrobial therapy are considered
resistant to colonization and will not be affected by exposure to C. difficile spores. Since,
on average, a patient’s microbiota will return to normal after 30 days [45], our model allows
susceptible patients to return to resistant if they are not exposed to C. difficile while
susceptible or if they do not receive an additional antibiotic in those 30 days. However,
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the susceptible individuals who do come into contact with C. difficile spores have a chance
of becoming colonized. Each individual susceptible patient has his or her own probability of
becoming colonized that changes at each 15-minute time-step and depends on the risk level
of the antibiotic prescribed and on the contamination level of his or her room. The more
contamination in a room, the greater the chances of exposure and subsequent colonization.
Similarly, the higher the antibiotic risk level with respect to C. difficile, the greater the
chances of colonization.
Upon colonization, patients are randomly assigned as either immunocompromised or not
immunocompromised, indicating whether or not they mount their own immune response
against the toxins produced during colonization. In keeping with the values used by Bintz
et al. [5], there is a 10% chance a colonized individual will be immunocompromised. All
colonized patients have a chance of receiving one or more additional antibiotics (for the
treatment of illnesses not related to C. difficile). For those who are not immunocompromised
and receive an additional antibiotic, it is possible they will clear their colonization but still
have an altered gut microbiota. Therefore, this subset of colonized patients may return to
susceptible. For colonized patients who are not immunocompromised and do not receive an
additional antibiotic, they may clear their colonization and also have their gut microbiota
return to normal. This subset of colonized patients will return to the resistant class. Finally,
those colonized who are immunocompromised will contract CDI. If they receive an additional
antibiotic prior to becoming diseased, this will shorten their incubation period and cause
them to experience CDI symptoms more quickly than they would have otherwise. Our
model includes screening of symptomatic patients for CDI with the turnaround time for the
screening test and the sensitivity of the screening test also incorporated. After the turnover
time for the screening test has elapsed, the symptomatic patients who were unsuccessfully
screened are tested again. Those diseased patients who are successfully screened for CDI will
be quarantined, and their symptoms will be treated with one of the typical antibiotics used
to treat CDI. There is an 80% chance of successful treatment and resolution of symptoms
[45] that will allow diseased patients to return to the susceptible class.
Upon arrival to the hospital, each HCW is assigned a shift length. For simplicity, we
consider either 8-hour or 12-hour shifts, with a 50% chance of each. We track each HCW’s
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Figure 3.2: Summary of movement among disease statuses of patients in agent-based model
time since beginning a shift, and once this time surpasses the total shift length assigned, that
HCW leaves the hospital. We divide HCWs into two groups: Type 1 and Type 2. Type 1
HCWs are assumed to be completing more routine, less time-consuming tasks and, therefore,
move from patient to patient every 15 minutes. In contrast, Type 2 HCWs spend more time
with the patients they visit and only move from patient to patient every 45 minutes. Our
model assumes that no HCW will visit a vacant room and that HCWs of the same type will
never be in the same room simultaneously; however, a Type 1 and Type 2 HCW may visit
the same patient at the same time.
HCWs have individual contamination levels that represent the amount of C. difficile they
are carrying. We do not track C. difficile colonization or infection of HCWs and view them
only as vehicles of pathogen spread from room to room. Because C. difficile is primarily
acquired nosocomially [48], we assume each HCW has a contamination level of zero upon
entry into the hospital. However, we should note that there has been a significant increase
in community-acquired infection by C. difficile [48], so this parameter can be varied to
mimic contamination from this increase. Each time an HCW visits a patient, the chances
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of becoming contaminated by C. difficile depends on the type of task being performed on
the patient and on the amount of contamination in the room. For this reason, we divide the
types of tasks HCWs complete into three groups: low-, medium-, and high-risk. The risk
associated with a particular task depends on the invasiveness of the task and the likelihood of
coming into contact with a large number of surfaces in the room. For example, we consider
a task such as giving a patient a scrub bath to put an HCW more at risk of becoming
contaminated than taking a patient’s temperature does. Although both types of HCWs can
perform any level of task, we assume Type 1 HCWs have a greater chance of performing
low-risk tasks while Type 2 HCWs have a greater chance of performing high-risk tasks.
3.2.3 Model processes
Before beginning simulations, the model environment is first initialized. In this process,
we populate the hospital with enough patients to meet the specified occupancy level. The
disease status of these patients upon admission is based on the admission proportions: ar,
as, ac, and ad, whose values are given in Table 3.12. The room contamination levels are then
initialized based on the disease status of the patient in the room. Rooms with resistant or
susceptible patients will have a contamination level of zero. Because colonized and diseased
patients will shed C. difficile spores, the contamination level of their rooms will be increased
to reflect this. The exact process for determining the amount of increase is the same as that
described in Section 3.8.4, where each submodel of the ABM is outlined. The hospital is
next populated with enough HCWs to maintain a 3:1 ratio of patients to HCWs, and the
contamination level of all HCWs is initialized to zero. In this initialization process, HCWs
are randomly assigned a length of time remaining on their shift, varying from 0 to 12 hours.
We let the model run for a three-week time period before recording outputs to ensure the
resulting outputs are not significantly dependent on the specified initial conditions.
After initialization, the model executes the following processes, in the order presented
below, at every 15-minute time-step. The flow of these processes is also illustrated in Figure
3.3.
1. New HCWs arrive to begin their shifts.
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1. New HCWs
begin shift
2. (Some) HCWs move to
visit new patients
3. Determine risk
level of task
being performed
4. Update HCW
and room
contamination levels
5. HCWs wash hands
upon leaving a patient
6. HCWs leave
hospital at conclusion
of their shift
(a) Determine
probability
of transfer
(b) Determine HCW
contact compliance
with quarantined patients
Figure 3.3: Summary of ABM processes that are run at each 15-minute time-step
2. If it is time to do so, HCWs move to begin a visit with a new patient; otherwise, they
do not move and continue their visit with the current patient.
3. Risk level of task being performed is determined.
4. HCW contamination levels and room contamination levels are updated based on the
transfer of C. difficile.
(a) The probabilities of transfer from HCW to room and vice versa are first
determined.
(b) Separate probabilities of transfer are determined for HCWs visiting quarantined
patients.
5. HCWs wash their hands at the conclusion of their patient visit.
6. HCWs who have completed their shifts leave the hospital.
To update the contamination levels of rooms and HCWs, we first determine the
probability of pathogen transfer occurring. When HCWs visit rooms, they have a chance of
picking up C. difficile spores, which would add to the existing contamination on their hands,
and they also have a chance of transferring C. difficile spores already on their hands to the
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room. The probability of an HCW picking up pathogen when visiting a room depends on the
amount of contamination in the room and the risk level of the task being performed. The
greater the room contamination and the higher the risk associated with the task, the more
likely an HCW will pick up pathogen from the room. Similarly, the probability of an HCW
transferring pathogen from his or her hands to a room surface depends on the contamination
level of the HCW and on the risk level of the task being performed. The more C. difficile on
an HCW’s hands and the higher the risk of the task, the more likely an HCW will transfer
pathogen to the room. We refer to the chance of HCWs picking up pathogen from the room
as prob-room-transfer and refer to the chance of HCWs transferring some of their existing
contamination to the room as prob-HCW-transfer. To calculate these probabilities at each
15-minute time-step for each HCW and room, we use three transfer functions, one for each
task risk level. When determining prob-room-transfer, we consider these transfer functions
to be functions of the room contamination level, and when determining prob-HCW-transfer,
we consider them to be functions of the HCW contamination level. For more details and
to see the specific functions used, refer to Section 3.8.9. Based on these probabilities, the
model then determines whether or not transfer will occur between a room and an HCW.
Note that the process of determining the probability of transfer between a room and an
HCW is different for quarantined patients. For these patients who were successfully identified
with CDI and then placed in isolation, there is either a 100% chance of transfer or 0% chance
of transfer between their room and the visiting HCW. We incorporate this into the model to
reflect the fact that HCWs are likely to behave differently when they know they are visiting
a patient quarantined with C. difficile. In fact, data shows a greater likelihood of HCWs
adhering to contact protocol when visiting patients in isolation. We refer to the likelihood of
HCWs complying with proper hand-hygiene and contact protocol when visiting quarantined
patients as hcw-contact-compliance and set its baseline value to 0.6, based on data given
by Rubin et al. [75]. If HCWs properly comply, there is a 0% chance of pathogen transfer
between that room and the HCW; if they do not, there is a 100% chance of transfer.
After determining whether transfer will occur for each HCW-room combination, the
model next updates HCW and room contamination levels to reflect the transfer. In
particular, if an HCW picks up pathogen from a room, we decrease the room contamination
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level by 10% and increase the HCW contamination level by that same amount to represent
the transfer. Similarly, if an HCW transfers pathogen to a room, we decrease the HCW
contamination level by 90% and increase the room contamination level by the same amount.
These percentages were chosen to reflect the fact that ward rooms contain many surfaces,
so one HCW is likely to only pick up a small percentage of the total contamination in the
room during one visit. In contrast, we are only tracking the contamination of HCWs on
their hands, so they are likely to transfer a vast majority of their total contamination to the
room if it is determined that a transfer will occur.
HCWs may decrease their contamination levels by following proper hand-washing and
contact protocols. Our model includes HCW routine hand-washing after every patient visit
with a 45% chance that the hand-washing was effective at reducing contamination. This
value was obtained by averaging the adherence percentage after patient contact of nurses
and physicians given by Rubin et al. [75]. We refer to this compliance as hcw-compliance
and set its baseline value to 0.45 (Table 3.12).
In addition to the processes run at each 15-minute time-step, the model will run the
following processes, in the order presented, at each half-day time-step. These processes are
also illustrated in the flow diagram in Figure 3.4.
1. Update the disease status of patients.
(a) Determine if each patient will receive an antibiotic (based on the global variable
for the overall probability of patients receiving antibiotics).
(b) Determine each patient’s probability of becoming colonized.
(c) Screen symptomatic patients for CDI.
(d) Quarantine and treat patients who tested positive for CDI.
2. Update the contamination level of rooms based on contributions from symptomatic
and asymptomatically colonized patients.
3. Discharge patients from the hospital (once their time since admission equals their
assigned length of stay).
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1. Update patient
disease status
2. Update room
contamination levels
from patient
contributions
3. Discharge
patients
4. Clean vacant
ward rooms
5. Admit new
patients
(a) Determine if
patient will
receive antibiotic
(b) Determine
patient’s probability
of colonization
(c) Screen
symptomatic patients
for CDI (d) Quarantine
and treat patients
who test positive
for CDI
Figure 3.4: Summary of ABM processes that are run at each half-day time-step
4. Clean vacant ward rooms.
5. Admit new patients to replace those who were discharged.
At each half-day time step, all patients have a 27% chance of receiving an antibiotic. This
number was chosen by Bintz et al. [5] so that the output for the total number of antibiotic
treatments per patient matched the data from the hospital. Whether or not a patient receives
an antibiotic will affect his or her disease status, as described in Section 3.2.2. When the
model updates each patient’s disease status, it first determines if that patient will receive an
antibiotic and then determines the risk level of the antibiotic given. In this step, the model
also updates the number of antibiotics each patient receives. The changes to disease status
were all described in Section 3.2.2 and are described in the most detail in Section 3.8.3.
After patient disease statuses are updated, the room contamination levels are updated
based on contributions from patients. As described in the initialization process, patients
with CDI and asymptomatically colonized patients contribute to the contamination level of a
room by shedding C. difficile spores in their feces. Resistant and susceptible patients will not
contribute. Note that our model does not explicitly include pathogen transfer directly from
HCW to patient or vice versa; rather, we model the transfer between HCWs and rooms and
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HCWs Rooms Patients
prob-HCW-transfer
prob-room-transfer
prob-becoming-colonized
shedding of spores
by colonized and
diseased patients
Figure 3.5: Summary of modes of C. difficile transmission included in the ABM, where
prob-room-transfer refers to the probability of an HCW picking up C. difficile spores from
a room, prob-HCW-transfer refers to the probability of an HCW contaminating room
surface(s) with spores, and prob-becoming-colonized represents the probability of a patient
becoming colonized based on the contamination level of the room and on the risk level of
the antibiotic received
between patients and rooms. Transfer between patients and HCWs is considered implicitly
as a result of the spread between rooms and HCWs and between rooms and patients. A
summary of all possible C. difficile transfer routes is represented in Figure 3.5.
Once the disease status of patients and room contamination levels are updated, patients
whose time since entering the hospital exceeds their length of stay assigned at admission
are discharged. After this, the model admits new patients to replace those who were just
discharged. This admission of patients is run in the same way patients were admitted
during the initialization process. When new patients are admitted, we assign them a disease
status and initialize all other patient characteristics that we are tracking. A complete list
of these patient characteristics is given in Section 3.7.3 of the ODD protocol, and a detailed
description of the admission of patients process run by the model is given in Section 3.8.2.
3.3 Control interventions
Our goal is to compare the impact of various control interventions, and combinations of
control interventions, on the transmission of and subsequent infection by C. difficile. We
consider the following intervention strategies:
1. Antimicrobial stewardship
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2. Increased HCW adherence to hand hygiene and contact protocol (with all patients and
specifically with quarantined patients)
3. Improved environmental decontamination
We consider antimicrobial stewardship in two forms (using the same techniques described
in [5]): (1) an overall reduction in the number of antibiotics prescribed and/or (2) a
reduction targeted at the proportions of high-risk and very high-risk antibiotics prescribed.
To implement an overall reduction in the number of antibiotics prescribed, we reduce the
half-daily probability of a patient receiving an antibiotic by a certain proportion. At baseline,
this reduction is assumed to be 0% so that there is a 27% chance of patients receiving an
antibiotic each half-day, as described by the global variable prob-antib listed in Table 3.12.
The intervention scenarios considered include a reduction of this probability by 10% and by
20%, resulting in a 24.3% and a 21.6% chance, respectively, of patients receiving an antibiotic
each half-day. For easy reference, these values are given in Table 3.1.
To implement the second form of antimicrobial stewardship, we alter the probabilities
of the antibiotic prescribed being low risk, high risk, or very high risk with respect to CDI.
The scenarios considered here are the same as those used by Bintz et al. [5] and are listed in
Table 3.2. In the baseline scenario, we set the proportion of low-risk antibiotics prescribed
to be 0.4, the proportion of high-risk to be 0.26, and the proportion of very high-risk to
be 0.34. We will refer to this as Risk Scenario 1. The second risk scenario considered
involves reducing the probability of very high-risk antibiotics being prescribed by half, and
as a result, increasing the probability of high-risk antibiotics being prescribed by that same
amount. The third and final risk scenario considered involves replacing both half of the
proportion of very high-risk antibiotics prescribed with high-risk antibiotics and half of the
high-risk antibiotics prescribed with low-risk antibiotics. As noted by Bintz et al. [5], these
particular antimicrobial stewardship strategies and values were chosen to represent programs
that could feasibly be implemented; more extreme values, such as a 0% chance of receiving
an antibiotic, are not realistic. Data indicate that even when hospitals were successfully
able to reduce the number of unnecessary antibiotics prescribed, there were always still some
unavoidable prescriptions, even at the very high-risk level, remaining [5].
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Table 3.1: Antimicrobial stewardship strategy: reduction in the overall number of
antibiotics prescribed
Probability of receiving antibiotic
baseline 0.27
10% reduction 0.243
20% reduction 0.216
Table 3.2: Antimicrobial stewardship strategy: reduction in the proportions of antibiotics
prescribed according to risk level with respect to CDI
Risk scenario 1 2 3
proportion of low-risk 0.4 0.4 0.53
proportion of high-risk 0.26 0.43 0.3
proportion of very high-risk 0.34 0.17 0.17
The next intervention strategy considered involves the increased adherence of HCWs to
hand-hygiene and contact protocols. To increase HCW compliance, a hospital might need
to have additional HCWs due to the time spent adequately sanitizing. Our model does
not explicitly account for the time HCWs spend adequately washing, but this is something
that could be further explored in the future. We consider both improved HCW hand-
hygiene compliance after each patient visit and improved HCW compliance when visiting
quarantined patients. The baseline value for HCW compliance after completing a routine
visit with a patient is 0.45, as mentioned in Section 3.2.3 to be taken from data given in [75],
and is referred to as hcw-compliance. To assess the impact of improved HCW adherence on
transmission and infection, we consider values greater than 0.45, including 0.65, 0.75, 0.85,
and 1. Although a compliance of 100% is not the most likely scenario, this extreme case
allows us to determine the impact of this particular control intervention. In addition to this
more routine HCW compliance, we also consider an increase in compliance when visiting
quarantined patients, referred to as hcw-contact-compliance. As mentioned in Section 3.2.3,
the baseline value for this compliance is 0.6, and we increase it by various amounts up to,
and including, 1 to assess the impact of this control strategy.
The third control intervention strategy considers improved environmental decontamina-
tion. Different types of cleaning and disinfection strategies will have varying impacts on
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the removal of C. difficile spores in the environment. Thus, we incorporate a probability
of sufficient cleaning into our model with a baseline value of 0.5 [5] that represents the
effectiveness of routine cleaning. An increased value of this probability indicates the
implementation of a more stringent and effective cleaning strategy that targets C. difficile.
For now, we only consider terminal cleaning of rooms after patients are discharged rather
than routine daily cleaning of all rooms.
3.4 High-performance computing setup
Because of the stochasticity embedded in ABMs, to best assess the impact of the control
intervention strategies, we ran our model for 100 iterations over a one-year simulated time
period with each combination of parameter values (representing different control strategies).
Since our model is on a 15-minute time-step, this requires simulating the model for over
35,000 ticks, 100 times each, for more than 40 different parameter combinations. It proved
to be very ineffective and time-consuming to run these computations on a single machine.
A common approach for dealing with such a large number of parameter combinations and
high numbers of iterations is to use computing clusters to enable parallelization and speed
up execution time. Therefore, we ran all simulations via the computing cluster available at
the Advanced Computing Facility (ACF), a high-performance computing facility available
for use by students and faculty at the University of Tennessee.
In order to submit jobs to the cluster efficiently, we worked closely with Eduardo Ponce
Mojica, a graduate student in the Department of Electrical Engineering and Computer
Science, to create a process for submission and for organizing the resulting outputs. The
process begins with the BehaviorSpace tool in NetLogo. This built-in NetLogo tool allows
us to specify the various parameter combinations we want to simulate and the resulting
outputs of interest. We then use the code created by BehaviorSpace to write a setup file.
To submit the job to the cluster, we use a PBS file that does the following: (1) specifies
the file path for the ABM, NetLogo, and the setup file, (2) calls the specified setup file,
(3) specifies a maximum run-time and number of nodes to use, and (4) includes code for
calling the Python file that orders and organizes the resulting simulation outputs according
56
to each parameter combination. For a more thorough description of this method, Mojica
has submitted a conference proceedings paper entitled “PaPaS: A Lightweight and Generic
Framework for Parallel Parameter Studies” [62] that outlines the details of the process for a
general NetLogo ABM to serve as a reference for those interested in doing something similar.
3.5 Results
To assess the impact of the control interventions, we examine the resulting number of
nosocomial colonizations and nosocomial infections over a year’s time period under each
particular control strategy. Because simulations result in varying numbers of total patient
admissions per year, we normalize all of the outputs to 10,000 admitted patients per year for
comparison. Without this normalization, comparison of colonization and disease incidence
can be misleading [5].
3.5.1 Baseline results
The baseline parameter values are given in Table 3.12 of Section 3.7.3, and the resulting
numbers of nosocomial colonizations and infections for the 100 iterations of the baseline
case are shown in the box plots in Figure 3.6. Note that the median values of nosocomial
colonizations and infections for the 100 iterations are indicated by the red lines, and
each box (outlined in blue) represents the inter-quartile range, which includes the middle
50% of output values. Specifically, the median number of nosocomial colonizations per
year at baseline, normalized to 10,000 admissions, was 2,161, and the median number of
nosocomial infections per year normalized to 10,000 was 111. Our numbers of nosocomial
colonizations per year are significantly lower than the numbers obtained in [5]; we adjusted
select parameters purposely (details in Section 3.8.13) so that our numbers of nosocomial
colonizations matched updated data indicating that nosocomial colonization incidence affects
20% of admitted patients [11, 40].
To obtain a better understanding of the types of patients becoming colonized and/or
diseased while hospitalized, we split up the total nosocomial colonizations and infections
according to each patient’s disease status at admission, with the results shown in Figure
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Figure 3.6: Baseline parameter values: Number of (a) nosocomial colonizations and (b)
nosocomial infections by C. difficile, normalized to 10,000 admissions, for 100 iterations over
a one-year time period with baseline parameter values
3.7. Figure 3.7a indicates that the majority of nosocomial colonizations are coming from
those who were resistant at admission while Figure 3.7b illustrates that the majority of
nosocomial infections come from those who are admitted colonized. The high number of
resistant patients becoming colonized while in the hospital is likely a result of the fact that
there is a 75% chance of patients being admitted resistant, so the number of resistant patients
hospitalized is much higher than that of any other disease status. In fact, only approximately
19.64% of the total number of admitted resistant patients become colonized (Table 3.3).
Still, the higher number of nosocomial colonizations coming from resistant patients suggests
that restricting antibiotic prescriptions in a way that keeps resistant patients from becoming
susceptible will be an important control strategy. Table 3.3 also indicates that the percentage
of admitted susceptible patients who become colonized is the highest of any admission class
(though not by a significant amount). This suggests that controlling the amount of C.
difficile in the environment and reducing possible exposure pathways will be an important
control strategy. Table 3.4 indicates that the largest percentage of admitted patients who
will contract CDI are those who are colonized upon admission.
58
0 10 20 30 40 50 60 70 80 90 100
Iteration number
0
200
400
600
800
1000
1200
1400
1600
1800
N
um
be
r o
f p
at
ie
nt
s
R to C
S to C
C to C
D to C
(a) Nosocomial colonizations
0 10 20 30 40 50 60 70 80 90 100
Iteration number
0
20
40
60
80
100
120
140
N
um
be
r o
f p
at
ie
nt
s
R to D
S to D
C to D
D to D
(b) Nosocomial infections
Figure 3.7: Breakdown of (a) nosocomial colonizations and (b) nosocomial infections based
on disease status at admission for 100 iterations over a one-year time period with baseline
parameter values
Table 3.3: Median percentage of patients admitted in each class who eventually become
colonized during their hospital stay out of 100 iterations
Admitted resistant who become colonized 19.64%
Admitted susceptible who become colonized 32.87%
Admitted colonized who clear colonization but then eventually
return to colonized
25.07%
Admitted diseased who return to susceptible and then become
colonized again
17.37%
Table 3.4: Median percentage of patients admitted in each class who eventually become
diseased during their hospital stay out of 100 iterations
Admitted resistant who become diseased < 1%
Admitted susceptible who become diseased < 1%
Admitted colonized who become diseased 5.56%
Admitted diseased who return to susceptible and then experience
recurrence
< 1%
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Figure 3.8: Reducing the half-daily probability of receiving an antibiotic: Resulting number
of (a) nosocomial colonizations and (b) nosocomial infections for baseline probability of
receiving an antibiotic (p = 0.27) and for the the reduced probabilities of receiving an
antibiotic (10% reduction and 20% reduction) described in Table 3.1, normalized to 10,000
admissions, for 100 iterations over a one-year time period
3.5.2 Single control interventions
We begin our assessment of control interventions by weighing the impact of each control
strategy implemented on its own on the numbers of nosocomial colonizations and infections.
In Section 3.3, we described two types of antimicrobial stewardship, and we consider
these first. Figure 3.8 illustrates the impact of reducing the overall number of antibiotics
prescribed, and Figure 3.9 shows the effect of reducing the proportions of very high-risk and
high-risk antibiotics with respect to CDI, according to the risk scenarios described in Table
3.2. In each graph, the first box plot corresponds to the baseline scenario for comparison.
Both of these antimicrobial stewardship strategies have a notable impact on reducing the
nosocomial colonizations (Figures 3.8a, 3.9a), and we see that reducing the proportions of
high-risk and very high-risk antibiotics has more of an impact on decreasing the nosocomial
infections (Figure 3.9b) than reducing the half-daily probability of receiving an antibiotic
has on reducing nosocomial infections (Figure 3.8b).
The next control strategy we implement is more effective terminal ward room cleaning.
Figure 3.10a indicates that this particular strategy is not as impactful as the antimicrobial
stewardship strategies at reducing nosocomial colonizations, even if 100% effective cleaning
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Figure 3.9: Reducing the proportion of very high-risk and high-risk antibiotics: Resulting
number of (a) nosocomial colonizations and (b) nosocomial infections for each risk scenario
(specifying proportions of low-risk, high-risk, and very high-risk antibiotics) described in
Table 3.2, where Risk Scenario 1 is baseline, normalized to 10,000 admissions, for 100
iterations over a one-year time period
is maintained. This result is similar to the conclusions made by Bintz et al. [5]. Additionally,
more effective cleaning has little impact on nosocomial infections (Figure 3.10b).
Another form of environmental decontamination is achieved by improved HCW adherence
to the best hand-hygiene and contact protocol. Figure 3.11a shows that increased HCW
compliance with all patients is more impactful on nosocomial colonizations than improved
room cleaning is; however, this general improved HCW compliance does not have a notable
impact on reducing nosocomial infections (Figure 3.11b). The results of improved HCW
compliance with quarantined patients is shown separately in Figure 3.12a. If HCWs achieve
100% compliance with quarantined patients, there is an extremely noticeable decrease in
nosocomial colonizations. Such a vast decrease is likely due to our model structure: if
HCWs are compliant with quarantined patients, there is a 0% chance of pathogen transfer
from HCW to room, or vice versa. This assumes that when fully compliant, HCWs will wear
gloves and strictly follow contact protocol so that there is no chance of exposure or transfer,
which is more likely to happen when HCWs know a patient is isolated due to symptomatic
CDI. This control strategy also results in a nice reduction of nosocomial infections (Figure
3.12b).
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Figure 3.10: Increasing the probability of sufficiently cleaning ward rooms: Resulting
number of (a) nosocomial colonizations and (b) nosocomial infections for increased
probabilities of sufficiently cleaning ward rooms, where 0.5 is baseline, normalized to 10,000
admissions, for 100 iterations over a one-year time period
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Figure 3.11: Increasing HCW compliance with all patients: Resulting number of (a)
nosocomial colonizations and (b) nosocomial infections for increased probabilities of HCWs
sufficiently cleaning their hands after visiting patients, where 0.45 is baseline, normalized to
10,000 admissions, for 100 iterations over a one-year time period
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Figure 3.12: Increasing HCW contact compliance with quarantined patients: Resulting
number of (a) nosocomial colonizations and (b) nosocomial infections for increased
probabilities of HCW contact compliance when visiting quarantined patients, where 0.6
is baseline, normalized to 10,000 admissions, for 100 iterations over a one-year time period
For easier comparison of individual control strategies, Table 3.5 gives the median numbers
of nosocomial colonizations and infections for the most extreme cases of each of the individual
strategies. We see that reducing the proportions of very high-risk and high-risk antibiotics
is the most effective strategy at reducing nosocomial infections while increasing HCW
contact compliance with quarantined patients has the largest impact on reducing nosocomial
colonizations. However, there is not one strategy that is best at reducing both nosocomial
colonizations and nosocomial infections simultaneously. It is essential for hospital policy to
not only consider how to effectively reduce infection incidence, but also colonization incidence
since these colonized individuals may develop CDI after leaving the hospital [5]. Discharging
colonized patients may will inevitably result in a subsequent increase in the admission of
diseased patients to healthcare facilities [5, 65] and to the amount of C. difficile in the
environment. Therefore, we next to compare the impact of various combinations of these
control strategies on both nosocomial colonizations and nosocomial infections.
3.5.3 Combination strategies
We begin this section by considering various combinations of antimicrobial stewardship and
improved cleaning. Initially considering the same scenarios as Bintz et al. [5] allows us to
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Table 3.5: Median numbers of nosocomial colonizations and nosocomial infections per year
for 100 iterations, normalized to 10,000 admissions, for the individual control scenarios listed
Median
nosocomial
colonizations
Median
nosocomial
infections
Baseline 2,161 111
Reduce antibs by 20% 1,740 103
Risk scenario 3 1,776 86
100% probability of effective cleaning 2,077 112
100% HCW compliance 1,843 106
100% HCW contact compliance (with quarantined patients) 952 93
compare our results to theirs and assess the impact of the modifications and extensions we
made to their ABM, such as the explicit inclusion of HCWs as agents. The combinations
of antimicrobial stewardship and cleaning considered were taken from [5] and are listed and
numbered in Table 3.6. Figure 3.13a displays the resulting median numbers of nosocomial
colonizations with the 27 strategies ordered in the way [5] determined most effective at
reducing colonizations while Figure 3.13b ranks the 27 control strategies according to
increasing median numbers of nosocomial colonizations resulting from our model. It is
immediately noticeable that, with our model, many of these strategies have a different impact
on nosocomial colonizations than they did on the resulting colonizations in [5].
First, note that the baseline scenario is indicated by Strategy 2. Comparison of Figures
3.13a and 3.13b shows that cleaning has less impact on nosocomial colonizations in our
model than it did using the model in [5]. We see that for our model there is only one
scenario (Strategy 1) worse than baseline at reducing nosocomial colonizations, compared to
five scenarios in [5] that were worse than baseline. In both cases, the strategies worse than
baseline all had less effective cleaning (specifically, a probability of effective cleaning set to
0.2). This insensitivity of less effective cleaning on nosocomial colonizations in our ABM
is further illustrated by the fact that the best-ranked strategies for our model are 27, 26,
and 25, which have varying levels of effective cleaning. The higher ranking of Scenario 25
for our model, even with its lower probability of effective cleaning, shows that antimicrobial
stewardship is more impactful than cleaning. With the addition of HCWs, we were able
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Figure 3.13: Combination strategies involving antimicrobial stewardship and ward room
cleaning: Resulting number of nosocomial colonizations for each of the 27 strategies listed
in Table 3.6 that incorporate both antimicrobial stewardship and ward room cleaning as
control interventions, normalized to 10,000 admissions, for 100 iterations over a one-year
time period, where the x-axis gives the strategies listed in order from the most effective
strategy to the least effective strategy for reducing nosocomial colonizations (a) based on
conclusions from Bintz et al.’s model [5] and (b) based on the results from our model
to consider room-level contamination, rather than ward-level contamination (as used in [5]),
when determining the probability of patients becoming colonized due to C. difficile exposure.
Thus, the cleanliness of the whole ward affected a patient’s likelihood of becoming colonized
in [5], so more effective cleaning could affect a larger number of patients’ probabilities of
colonization. Despite these model differences, we still come to the same conclusion as [5]
with respect to this combination of control strategies: even in the event of less sufficient
ward room cleaning, antimicrobial stewardship is noticeably effective at reducing nosocomial
colonizations.
The numbers of nosocomial infections resulting from the 27 combination control strategies
listed in Table 3.6, ordered the same way as those in Figure 3.13b (based on resulting median
numbers of nosocomial colonizations), are illustrated in Figure 3.14a. For comparison, Figure
3.14b also illustrates the numbers of nosocomial infections for the 27 strategies, but they are
ordered according to increasing median number of nosocomial infections. From these figures,
we can conclude that Strategies 26 and 27 are the best two strategies for reducing both the
nosocomial colonizations and infections simultaneously while Strategies 1 and 2 (baseline)
are the worst for both.
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Table 3.6: Antimicrobial stewardship and ward room cleaning combination strategies
numbered for easy reference, where the specific distributions of antibiotic-risk-level
probabilities for each risk scenario are given in Table 3.2
Combination
number
Half-daily antibiotic
probability
Risk scenario Probability of sufficient
cleaning
1 0.27 1 0.2
2 0.27 1 0.5
3 0.27 1 0.8
4 0.27 2 0.2
5 0.27 2 0.5
6 0.27 2 0.8
7 0.27 3 0.2
8 0.27 3 0.5
9 0.27 3 0.8
10 0.243 1 0.2
11 0.243 1 0.5
12 0.243 1 0.8
13 0.243 2 0.2
14 0.243 2 0.5
15 0.243 2 0.8
16 0.243 3 0.2
17 0.243 3 0.5
18 0.243 3 0.8
19 0.216 1 0.2
20 0.216 1 0.5
21 0.216 1 0.8
22 0.216 2 0.2
23 0.216 2 0.5
24 0.216 2 0.8
25 0.216 3 0.2
26 0.216 3 0.5
27 0.216 3 0.8
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Figure 3.14: Combination strategies involving antimicrobial stewardship and ward room
cleaning: Resulting number of nosocomial infections for each of the 27 strategies listed
in Table 3.6 that incorporate both antimicrobial stewardship and ward room cleaning as
control interventions, normalized to 10,000 admissions, for 100 iterations over a one-year
time period, where the x-axis gives the strategies listed (a) in order of increasing resulting
median number of nosocomial colonizations determined in Figure 3.13b and (b) in order of
increasing resulting median number of nosocomial infections
Next, we consider the addition of improved HCW compliance to the current combinations
of antimicrobial stewardship with improved cleaning. To keep the number of parameter
combinations under control, we select 5 of the 27 strategies listed in Table 3.6 to be
representative of their varying effects on nosocomial colonizations and infections. To these 5
strategies (Strategies 6, 15, 18, 22, and 25), we incorporate improved HCW compliance. We
consider three values for HCW compliance with non-quarantined patients: 0.45 (baseline),
0.75, and 1, and we consider two values for HCW contact compliance with quarantined
patients: 0.6 (baseline) and 1. The resulting 15 parameter combinations considered are
listed and numbered in Table 3.7. We will consider these 15 combinations first with baseline
HCW contact compliance with quarantined patients and then all 15 combinations again
with the increased HCW contact compliance. The results for these 15 combinations with
baseline HCW contact compliance are shown in Figure 3.15a and those with 100% contact
compliance with quarantined patients are illustrated in Figure 3.15b. Similar plots are given
for the resulting number of nosocomial infections (Figures 3.16a and 3.16b).
Figure 3.15a shows that scenarios 25.2, 18.2, and 18.1 are most effective at reducing
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nosocomial colonizations. These four scenarios implemented Risk Scenario 3 (Table 3.2),
which accounts for the most extreme reductions in high-risk and very high-risk antibiotics.
The next two best scenarios, 22.2 and 15.2, surpassed Scenarios 25.0 and 18.0 (that
implement Risk Scenario 3 but only consider baseline HCW compliance) in their effectiveness
at reducing nosocomial colonizations. This is one example of many observations we made
that often a more extreme version of one control (such as HCW compliance) can compensate
for a less extreme version of another (such as a smaller reduction in the overall antibiotic
probability). We do not, however, see this same trend when HCW contact compliance with
quarantined patients is increased to 100% (Figure 3.15b). In this case, Scenario 25 is always
better than the remaining 4 strategies for all values of general HCW compliance. This is
expected since increasing HCW contact compliance with quarantined patients leads to less
overall pathogen transfer between HCWs and rooms, so nosocomial colonizations are no
longer as sensitive to changes in general HCW compliance.
The resulting ranking of control scenarios for nosocomial infections matches what we
discovered when running the control scenarios individually. In particular, we saw that Risk
Scenario 3 was the most effective at reducing nosocomial infections, and we see in Figures
3.16a and 3.16b that all of the strategies from Table 3.7 with Risk Scenario 3 (18.0, 18.1,
18.2, 25.0, 25.1, 25.2) were the most effective at reducing nosocomial infections, regardless
of the values of other parameters.
3.5.4 Vaccination
The control scenarios and combinations of controls considered so far were all more impactful
on reducing the number of nosocomial colonizations than on reducing the number of
nosocomial infections. They all targeted the reduction of C. difficile in the environment and
the reduction of patients’ susceptibility to colonization more intensely than the prevention of
progression from colonized to diseased. Because there has been an increase in the percentage
of patients admitted already colonized by C. difficile, many colonized patients will not be
affected by the control scenarios we have considered. Therefore, considering a control scenario
that will inhibit a patient’s transition from colonized to diseased, such as a toxoid vaccine,
would be a beneficial addition to the other controls considered.
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Table 3.7: Parameter combinations representing control interventions with increased HCW
compliance (where 0.45 is baseline) combined with select combinations of antimicrobial
stewardship and ward room cleaning (Scenarios 6, 15, 18, 22, and 25 from Table 3.6)
Combination
number
Half-daily
antibiotic
probability
Risk
scenario
Probability
of sufficient
cleaning
HCW
compliance
(all
patients)
6.0 0.27 2 0.8 0.45
6.1 0.27 2 0.8 0.75
6.2 0.27 2 0.8 1
15.0 0.243 2 0.8 0.45
15.1 0.243 2 0.8 0.75
15.2 0.243 2 0.8 1
18.0 0.243 3 0.8 0.45
18.1 0.243 3 0.8 0.75
18.2 0.243 3 0.8 1
22.0 0.216 2 0.2 0.45
22.1 0.216 2 0.2 0.75
22.2 0.216 2 0.2 1
25.0 0.216 3 0.2 0.45
25.1 0.216 3 0.2 0.75
25.2 0.216 3 0.2 1
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Figure 3.15: Combination strategies involving antimicrobial stewardship, ward room
cleaning, and HCW compliance: Resulting number of nosocomial colonizations for each of
the 15 strategies listed in Table 3.7 that incorporate antimicrobial stewardship, ward room
cleaning, and HCW compliance as control interventions, normalized to 10,000 admissions, for
100 iterations over a one-year time period, where the x-axis (a) corresponds to the strategies
in Table 3.7 with HCW contact compliance with quarantined patients equal to 0.6 and (b)
corresponds to the strategies in Table 3.7 with HCW contact compliance with quarantined
patients equal to 1
25.2 18.1 18.2 25.1 18.0 25.0 22.2 22.1 15.2 15.1 6.2 22.0 15.0 6.1 6.0
Scenario
60
70
80
90
100
110
120
N
os
oc
om
ia
l i
nf
ec
tio
ns
 in
 o
ne
 y
ea
r
(a) HCW contact compliance = 0.6
18.2 25.2 25.0 25.1 18.1 18.0 22.0 22.1 15.0 6.0 22.2 6.1 15.1 15.2 6.2
Scenario
50
60
70
80
90
100
110
N
os
oc
om
ia
l i
nf
ec
tio
ns
 in
 o
ne
 y
ea
r
(b) HCW contact compliance = 1
Figure 3.16: Combination strategies involving antimicrobial stewardship, ward room
cleaning, and HCW compliance: Resulting number of nosocomial infections for each of
the 15 strategies listed in Table 3.7 that incorporate antimicrobial stewardship, ward room
cleaning, and HCW compliance as control interventions, normalized to 10,000 admissions, for
100 iterations over a one-year time period, where the x-axis (a) corresponds to the strategies
in Table 3.7 with HCW contact compliance with quarantined patients equal to 0.6 and (b)
corresponds to the strategies in Table 3.7 with HCW contact compliance with quarantined
patients equal to 1
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The C. difficile vaccine currently being tested is a toxoid vaccine, meaning that it will
only fight against clinical infection and will not protect against colonization by C. difficile.
Therefore, an effective version of this vaccine would result in a decrease in the proportion
of immunocompromised patients. We perform a preliminary assessment of vaccination by
making the strong assumption that a vaccination program has been successfully implemented
in the hospital for a period of time such that it has already resulted in an overall reduction in
the percentage of immunocompromised patients. To simulate this, we decrease the baseline
value for the probability of a patient being immunocompromised from 10%, used by Bintz
et al. [5], down to values such as 5% or 1%. Note that this a simplified implementation
of vaccination because it relies on the major assumptions that all patients at risk will be
vaccinated and will be vaccinated effectively. Our future work will involve the addition of
a vaccinated disease class, a probability of patients being vaccinated, and a vaccine efficacy
probability to more thoroughly assess the impact of vaccination as a control strategy.
We begin by implementing vaccination individually with no other controls. As expected,
since vaccination does not prevent colonization, it has a large impact on the nosocomial
infections (Figure 3.17b) and a minimal impact on the nosocomial colonizations (Figure
3.17a). To avoid an excessive number of parameter combinations, we selected 8 scenarios
from Table 3.7 (6.1, 6.2, 18.1, 18.2, 22.1, 22.2, 25.1, and 25.2) to which we added vaccination.
The resulting combinations are numbered and labeled in Table 3.8. Figure 3.18 shows the
resulting number of nosocomial colonizations for each of the control combinations in Table
3.8.
We observed that vaccination in combination with other control techniques did not
change the effectiveness of those scenarios at reducing colonizations in the absence of
vaccination (Figure 3.18b). That is, the same scenarios we found to be most effective
at reducing nosocomial colonizations in the absence of vaccination were still the most
effective once vaccination was added. Furthermore, vaccination in combination with other
control techniques had a similar impact on reducing nosocomial infections as it did when
implemented in the absence of additional controls, as illustrated by Figure 3.19. Thus,
if a healthcare facility is able to implement a vaccination program that would lead to a
reduction in the probability of patients being immunocompromised to 5% or 1%, then they
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Figure 3.17: Reducing probability of being immunocompromised as a form of effective
vaccination: Resulting number of (a) nosocomial colonizations and (b) nosocomial infections
for decreasing probabilities of being immunocompromised, where 0.10 is baseline, normalized
to 10,000 admissions, for 100 iterations over a one-year time period
would experience a significant decrease in the number of nosocomial infections but not a
notable change in nosocomial colonizations.
3.6 Discussion
Because C. difficile can survive on environmental surfaces for extended time periods [28],
there is benefit to incorporating environmental transmission when modeling its spread in
healthcare facilities. To consider the roles of contaminated environments and of both
symptomatic and asymptomatic carriers as C. difficile reservoirs, we developed an ABM (a
modification and extension of the ABM in [5]) that explicitly incorporates HCWs as vectors
of transmission, tracks individual patient antibiotic histories, incorporates varying risk levels
of antibiotics with respect to CDI, and tracks contamination of ward rooms by C. difficile.
We use this ABM to simulate and evaluate the impact of different control strategies on the
resulting numbers of nosocomial colonizations and infections by C. difficile. The control
strategies considered included two forms of antimicrobial stewardship (overall reduction
in antibiotics and a reduction of specifically high-risk and very-risk antibiotics), increased
environmental decontamination through room cleaning, improved HCW compliance with
quarantined and non-quarantined patients, and a preliminary assessment of vaccination. To
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Table 3.8: Parameter combinations representing control interventions with decreased
probability of being immunocompromised (where 0.10 is baseline), combined with select
combinations of improved HCW compliance, antimicrobial stewardship, and ward room
cleaning (Scenarios 6.1, 6.2, 18.1, 18.2, 22.1, 22.2, 25.1, and 25.2 from Table 3.7)
Combination
number
Half-daily
antibiotic
probability
Risk
scenario
Probability
of sufficient
cleaning
HCW
compliance
Probability of
being immuno-
compromised
6.1.0 0.27 2 0.8 0.75 0.10
6.1.1 0.27 2 0.8 0.75 0.05
6.1.2 0.27 2 0.8 0.75 0.01
6.2.0 0.27 2 0.8 1 0.10
6.2.1 0.27 2 0.8 1 0.05
6.2.2 0.27 2 0.8 1 0.01
18.1.0 0.243 3 0.8 0.75 0.10
18.1.1 0.243 3 0.8 0.75 0.05
18.1.2 0.243 3 0.8 0.75 0.01
18.2.0 0.243 3 0.8 1 0.10
18.2.1 0.243 3 0.8 1 0.05
18.2.2 0.243 3 0.8 1 0.01
22.1.0 0.216 2 0.2 0.75 0.10
22.1.1 0.216 2 0.2 0.75 0.05
22.1.2 0.216 2 0.2 0.75 0.01
22.2.0 0.216 2 0.2 1 0.10
22.2.1 0.216 2 0.2 1 0.05
22.2.2 0.216 2 0.2 1 0.01
25.1.0 0.216 3 0.2 0.75 0.10
25.1.1 0.216 3 0.2 0.75 0.05
25.1.2 0.216 3 0.2 0.75 0.01
25.2.0 0.216 3 0.2 1 0.10
25.2.1 0.216 3 0.2 1 0.05
25.2.2 0.216 3 0.2 1 0.01
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(a) Nosocomial colonizations with scenarios in the order listed in Table 3.8
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(b) Nosocomial colonizations with scenarios ordered according to increasing number of colonizations
Figure 3.18: Combination strategies involving antimicrobial stewardship, ward room
cleaning, HCW compliance, and vaccination: Resulting number of nosocomial colonizations
for each of the 24 strategies listed in Table 3.8 that incorporate antimicrobial stewardship,
ward room cleaning, HCW compliance, and vaccination as control interventions, normalized
to 10,000 admissions, for 100 iterations over a one-year time period, where the x-axis (a)
lists the scenarios in the order presented in Table 3.8 and (b) lists the scenarios according
to increasing number of colonizations
74
6.1.0 6.1.1 6.1.2 6.2.0 6.2.1 6.2.2 18.1.0 18.1.1 18.1.2 18.2.0 18.2.1 18.2.2 22.1.0 22.1.1 22.1.2 22.2.0 22.2.1 22.2.2 25.1.0 25.1.1 25.1.2 25.2.0 25.2.1 25.2.2
Scenario
0
20
40
60
80
100
N
os
oc
om
ia
l i
nf
ec
tio
ns
 in
 o
ne
 y
ea
r
Figure 3.19: Combination strategies involving antimicrobial stewardship, ward room
cleaning, HCW compliance, and vaccination: Resulting number of nosocomial infections
for each of the 24 strategies listed in Table 3.8 that incorporate antimicrobial stewardship,
ward room cleaning, HCW compliance, and vaccination as control interventions, normalized
to 10,000 admissions, for 100 iterations over a one-year time period, where the x-axis lists
the scenarios in the order presented in Table 3.8
improve HCW compliance, a hospital would need to bring in additional HCWs due to the
time needed to adequately sanitize. Although our model does not explicitly account for the
time HCWs spend adequately washing, this is something that could be further explored in
future work.
We illustrated the efficacy of each of the control interventions individually and in various
combinations on reducing the numbers of nosocomial colonizations and infections in order
to determine where control efforts should be concentrated. It is important for hospitals
to implement strategies that are effective at decreasing incidence of both infection and
colonization by C. difficile [5]. However, in our modeling study, we demonstrated that there
was no single strategy that was best at reducing nosocomial colonizations and nosocomial
infections simultaneously. In particular, improved cleaning did not have a significant impact
on either while improved HCW compliance with all patients proved to be effective at
reducing colonizations but was not impactful on reducing nosocomial infections. Both forms
of antimicrobial stewardship were shown to be effective at decreasing colonizations, and
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both had a more notable impact on reducing nosocomial infections than did cleaning or
improved HCW compliance (with all patients and specifically with quarantined patients).
Increased HCW compliance with quarantined patients was more notable in its impacts
on both nosocomial colonizations and infections than increased HCW general compliance.
Overall, targeted reduction of high-risk and very high-risk antibiotics with respect to CDI was
the most effective strategy at reducing nosocomial infections, and increased HCW compliance
with quarantined patients was most effective at reducing nosocomial colonizations.
Additionally, we determined that when the control strategies are combined in various
ways, a more extreme version of one control could often compensate for a less extreme
version of another to effectively reduce nosocomial colonizations. We also determined that
the resulting impact of the control scenarios on nosocomial colonizations and infections
were not completely additive. In particular, the reduction in nosocomial colonizations (or
infections) made by a particular combination strategy was not equal to the sum of the
reduction made by the strategies individually.
Because an increased number of patients are coming into hospitals already colonized, we
considered an additional control strategy that would prevent these patients from progressing
to diseased. In particular, we performed a preliminary evaluation of vaccination in order to
assess how a vaccine would impact the resulting colonizations and infections in a hospital
both on its own and in combination with other control strategies. As expected, vaccination
had a large impact on disease incidence with little impact on nosocomial colonizations
since the C. difficile toxoid vaccine does not prevent colonization, but only subsequent
infection. This preliminary assessment of vaccination comes with strong assumptions and
is considered the best case scenario. Results such as these may help hospitals determine
what kind of vaccination strategy would be necessary to achieve the desired results and the
implementation feasibility of such a strategy. In the future, we would like to expand our
preliminary assessment of vaccination by including vaccine efficacy at the individual patient
level and a protocol efficacy to more thoroughly evaluate the impact of vaccination as a
control measure.
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3.7 ODD Protocol: Overview
In this section, we describe the Overview, Design concepts, and Details (ODD) of our agent-
based model to provide a more complete and rigorous model description. ODD was designed
by experienced modelers to create a complete, quick, and exhaustive method for describing
agent-based models for the purpose of standardization and replication [72].
3.7.1 Purpose
We modified and expanded the agent-based model in [5], which simulates the transmission
of C. difficile in a healthcare setting. In particular, we explicitly incorporated healthcare
workers as vectors of transmission and then evaluated the following: (1) the efficacy of control
measures such as antimicrobial and environmental stewardship and (2) the impact of HCWs
on the spread of nosocomial CDI.
3.7.2 Input data
The agent behaviors, parameter values, and initial conditions are based on information
from either published literature or data collected from six medicines wards at Barnes-Jewish
Hospital in St. Louis, Missouri. Information about the collection of this data is described by
Lanzas et al. in [45]. We also incorporated updated hospital data that was collected after
the publication of [45], such as an increased admission of colonized patients, described by
Alasmari et al. [1].
By varying model inputs, we simulated and compared the impact of a variety of control
measures on reducing nosocomial colonization and infection. The first such strategy involved
varying the probability of effective cleaning. As in the original ABM in [5], we defined
effective cleaning to be “cleaning that reduces the contamination level of a ward room.”
The cleanliness, or lack thereof, of each ward room affects the probability that a patient
will become colonized, so increasing the probability of effective cleaning serves as a disease
control measure.
Because healthcare workers are the only agents that move from room to room, they are
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important vectors of spore transmission, so our second control strategy involved varying
healthcare worker (HCW) compliance and HCW contact compliance. HCW compliance is
defined as the level of compliance that HCWs adhere to when washing their hands after
visiting patients. Our baseline value for HCW compliance was based on the values given
by Rubin et al. in [75].We define HCW contact compliance to be the level of compliance
that HCWs adhere to after visiting a quarantined patient. Data indicates that HCWs are
more compliant with hand-washing and other contact precautions when they know they are
visiting an infected patient. We set the baseline value of this variable to be 0.6 to match the
data for percentage of adherence to the use of contact precautions in isolation rooms given
in [75].
Antimicrobial stewardship was determined in [5] to be another important control measure.
One method of implementing antimicrobial stewardship involves reducing the overall number
of antibiotics given to patients. We implement this in the same way that Bintz et al. do in
[5]: define q to be the proportion by which we want to reduce antibiotic treatments in the
hospital. Then, out of all patients who will receive an antibiotic at each time-step, determined
by the probability of receiving an antibiotic, only 1−q of them will now receive an antibiotic.
A second method of antimicrobial stewardship involves altering the relative proportions of
antibiotics given. As in [5], we define three risk levels of antibiotics prescribed (low, high,
or very high) based on whether they make patients more or less at risk of contracting CDI.
The baseline values for the probability of receiving a low-risk, high-risk, or very-high-risk
antibiotic (0.4, 0.26, and 0.34, respectively) were taken from the data and are the same as
those used in [5]. Control strategies considered involve decreasing the proportion of very-
high-risk antibiotics prescribed.
3.7.3 Entities, state variables, and scales
Our ABM has three entities: patients, healthcare workers, and ward rooms. The model was
designed to mimic characteristics of Barnes-Jewish Hospital, from where the original data
was obtained. As such, we considered a hospital with six medical wards of 35 rooms each,
with at most one patient occupying a room at any given time. This allowed for a total
possible capacity of 210 patients, and we set the baseline occupancy level to be 0.85. Patient
78
Table 3.9: Room state variable explanations and values
Room Variable Description
Possible
Value(s)
ward-number Specifies in which ward the room is located 1, 2, ..., 6
contamination-level Tracks the amount of contamination in room [0,∞)
quarantine-patient-
here
Specifies whether or not current occupant is under
quarantine
yes, no
prob-room-transfer
Gives the probability the room will transfer
pathogen to an HCW
[0, 1]
state variables are updated on a half-day time scale, which reflects the time-step used in [5].
HCW state variables are updated every 15 minutes to reflect their movement from room to
room.
Room State Variables Each ward room is characterized by four state variables, listed
in Table 3.9. First, each room is assigned to a specific ward. Next, all rooms have a
contamination level that is updated on the 15-minute time-step scale. HCWs can increase the
contamination level of a room upon entering, depending on prob-hcw-transfer, the probability
that an HCW will transfer pathogen to the room, described more in Section 3.8.9. Each half-
day symptomatic and asymptomatic patients contribute to the contamination level of a room.
Effective cleaning can reduce the contamination level of a room, and cleaning is implemented
each half day only after a patient is discharged from that room. The contamination level
of an individual room affects the probability that a susceptible patient in that room will
become colonized.
The next state variable that governs room characteristics is whether or not a room is
occupied by a patient under quarantine. According to [29], symptomatic patients are placed
in quarantine to ensure proper contact precautions are implemented. Finally, a room is
characterized by the state variable prob-room-transfer. This probability is updated each
15-minute time-step and determines the likelihood of an HCW picking up pathogen upon
entering that particular room. More information about determining this probability is also
described in Section 3.8.9.
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Patient State Variables Patient behavior is characterized by many state variables, all of
which are listed in Table 3.10. A patient’s disease status is tracked beginning at admission. A
patient can either be resistant to contracting CDI, susceptible to contracting CDI, colonized
by C. difficile (asymptomatic), or diseased (symptomatic CDI). Because taking an antibiotic
is the strongest risk factor for contracting CDI [48], our assumption is that any patient who
has not received an antibiotic is resistant to CDI. In particular, it has been shown that more
than 90% of patients of hospitalized patients with CDI recently underwent antimicrobial
therapy [19]. Once an antibiotic is given, a patient becomes susceptible to colonization.
Depending on a patient’s probability of becoming colonized, a susceptible patient who
comes into contact with C. difficile spores may become colonized and, therefore, become
an asymptomatic carrier.
A patient either will or will not be immunocompromised. An immunocompromised
patient is a colonized patient who is unable to mount his or her own immune response
and, therefore, will contract CDI. Those who are not immunocompromised are able to
mount an immune response and will not experience CDI symptoms. Each susceptible
and asymptomatically colonized patient has a probability of his or her gut microbiota
returning to normal (and therefore regaining resistance). If a colonized patient is not
immunocompromised and receives an antibiotic, it is possible to revert to being susceptible;
if he or she is immunocompromised and does not receive an antibiotic, it is possible to
regain resistance. An immunocompromised colonized patient who receives an antibiotic will
contract CDI more quickly than immunocompromised patients who do not receive antibiotics.
The movement among disease states are illustrated in Figure 3.2.
Each patient that is admitted is assigned a length of stay based on his or her disease
status. Patients’ time since admission and time since current disease status are both tracked
while, for patients who have received an antibiotic, their time since beginning antibiotics
is tracked in addition to the risk level (low, high, or very high) of the antibiotic taken and
the number of antibiotics taken. Diseased patients may or may not be identified as diseased
upon screening, and their time since a successful screening is tracked. Additionally, diseased
patients who are successfully identified may or may not be treated successfully, and their
time since beginning treatment is tracked.
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Table 3.10: Patient state variable explanations and values
Patient Variable Description
Possible
Value(s)
disease-status Tracks patient disease status R,S,C,D
disease-status-at-
admission
Identifies patient disease status upon admission R,S,C,D
length-of-stay
Specifies a patient’s length of stay in the hospital
(half-days)
[0, 160]
time-since-admission
Tracks amount of time since patient was admitted
(half-days)
0, 1, 2, ...
time-since-current-
disease-status
Tracks amount of time since patient current disease
status began
0, 1, 2, ...
immunocompromised
Indicates whether or not a patient will mount an
immune response to colonization
yes, no
treatment-length
Gives prescribed length of current antibiotic
treatment (half-days)
14
time-to-normal
Gives time until patient’s gut microbiota returns to
normal (half-days)
low-risk antibiotic 28
high-risk antibiotic 28
very-high-risk antibiotic 70
time-since-began-
antib
Tracks time since patient began current antibiotic
treatment (half-days)
0, 1, 2, ...
prob-regaining-
resistance
Gives the probability of regaining resistance to
colonization
[0, 1]
prob-becoming-
colonized
Gives the probability of a susceptible patient
becoming colonized
[0, 1]
antib-risk-level
Indicates the risk level of the current antibiotic with
respect to CDI
low, high,
very-high
number-hosp-antibs
Tracks the number of antibiotics a patient has
received
0, 1, 2, ...
length-incubation-
period
Gives the length of time between colonization and
becoming diseased (half-days)
low-risk antibiotic [20, 60]
high-risk antibiotic [14, 40]
very-high-risk antibiotic [8, 20]
time-until-diseased
Gives the length of time until an immunocompro-
mised, colonized patient becomes diseased (half-
days)
[0, 60]
will-ID
Indicates whether a screening will correctly test
positive for CDI
yes, no
time-since-succ-
screen
Tracks the amount of time since patient correctly
tested positive for CDI (half-days)
0,1,2...
will-treat-succ
Determines whether a patient will be treated for
CDI successfully
yes, no
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Healthcare Worker State Variables HCWs are initially assigned a ward, and it is
assumed HCWs visit only patients in that same ward for the entirety of their shift. Each
HCW is assigned a shift length upon entry to the hospital, and an HCW’s time since
beginning a shift is tracked. There is a 50% chance an HCW will have an 8-hour shift
and a 50% chance an HCW will work a 12-hour shift. Healthcare workers are divided into
two types: Type 1 HCWs visit many patients for short periods of time (assumed to be 15
minutes), and Type 2 HCWs visit fewer patients for longer periods of time (assumed to be
45 minutes). Type 1 HCWs move systematically from room to room, meaning that they
move to the next closest occupied room at each 15-minute time-step. Type 2 HCWs move
randomly from room to room within the same ward. It is assumed there will never be more
than one Type 1 HCW or more than one Type 2 HCW in a given room simultaneously;
however, there can be a Type 2 and a Type 1 HCW visiting the same patient at the same
time. HCWs will never enter rooms not occupied by a patient.
All HCWs have individual contamination levels similar to the contamination levels
tracked for each ward room. We refer to HCWs’ contamination levels as their carrier level,
which represents the amount of pathogen on their hands. For simplicity, we assume that
all HCWs begin their shifts with carrier levels of zero; however, this could soon need to
be increased as data indicates community-associated CDI is increasing [87]. Once in the
hospital, HCW carrier levels can be increased upon picking up pathogen in contaminated
rooms and can be decreased by adherence to proper hand-washing and contact precaution
protocols. Each HCW has a probability of transferring pathogen to a room upon entry,
referred to as prob-hcw-transfer (Section 3.8.9).
Not only does the time HCWs spend with patients vary, but also the type of task they
perform on a patient can affect their probability of picking up C. difficile spores. We define
three task levels (low risk, medium risk, or high risk) based on the risk of transfer. HCWs
can perform any risk level task, but we assume Type 1 HCWs are more likely to perform
low-risk tasks while Type 2 HCWs are more likely to perform high-risk tasks. A list of all
HCW variable values along with explanations is given in Table 3.11.
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Table 3.11: HCW state variable explanations and values
HCW Variable Description
Possible
Value(s)
shift-length Specifies length of HCW’s shift (hours) 8, 12
time-since-shift-
began
Tracks the time since an HCW began a shift (hours) [0, 12]
carrier-level
Tracks amount of contamination on an HCW’s
hands
[0,∞)
hcw-type
Indicates whether an HCW will be Type 1 or Type
2
Type 1, Type 2
hcw-risk
Indicates the risk level of the task an HCW is
performing
low, medium,
high
prob-hcw-transfer
Gives the probability an HCW will transfer
pathogen to a room
[0, 1]
Global State Variables A summary description of all global variables is given in Table
3.12. Admission proportions for each disease status (ar, as, ac, and ad) are global variables
based on the Barnes-Jewish Hospital data detailed in [45] with modifications made based
on the updated data in [1]. This new data indicated that 15% of admitted patients were
colonized upon arrival, so we updated ac and thereby decreased as to reflect this. Thus, we
set the probability of a patient being colonized upon admission to 0.15, the probability of a
patient being susceptible upon admission to 0.09, the probability of a patient being resistant
upon admission to 0.75, and the probability of a patient having CDI upon admission to 0.01.
The probability of an HCW complying with proper hand-washing and contact precaution
protocol after leaving a room has a baseline value of 0.45. In particular, we averaged the
percentage of hand-hygiene adherence for nurses and doctors in non-isolated rooms given in
[75]. The probability an HCW who has just visited a quarantined patient will follow proper
protocol is set slightly higher to 0.6 to match the percentage of adherence to the use of
contact precautions in isolation rooms given in [75]. The percentage of total contamination
that an HCW will transfer to a room after determining transfer will occur is a global variable
set to 90% while the percentage of pathogen a room will transfer to an HCW is set to
10%. Assessments of hospital cleaning practices have shown that routine cleaning results
in decontamination of no more than 56% of targeted surfaces [28]. If a room is effectively
cleaned, we set the contamination level to be reduced by 50%.
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The probability of susceptible patients becoming colonized depends on both the
contamination level of their room and the risk level of their current antibiotic. Similar
to antibiotic risks, room contamination levels are divided into three groups (low, medium,
or high contamination). Rooms with contamination levels between 0 and 0.4 are considered
low contamination while rooms with contamination levels between 0.4 and 0.8 are considered
to have medium contamination. Any rooms with contamination levels higher than 0.8 are
considered highly contaminated. Each probability of becoming colonized is denoted with
a subscript referring to the antibiotic-risk level and a superscript referring to the room-
contamination level. For example, phl is the probability a patient on a low-risk antibiotic
becomes colonized in a highly contaminated room. Probabilities for each combination of
antibiotic-risk level and room-contamination level are denoted in a similar way. Values for
each of these probabilities and for the room-contamination cut-off levels were chosen so that
nosocomial colonizations accounted for 20% of admissions [11, 40]. More details about these
calculations are given in Section 3.8.13.
All global variables described in the remainder of this section are kept the same as those
used in the original ABM in [5]. We define the hospital occupancy level to be a global
variable that is set to 0.85. The probability a patient is immunocompromised is a global
variable with baseline value 0.1. To determine the probability that a susceptible or not-
immunocompromised colonized patient will regain resistance, we define a global variable
for the minimum probability of regaining resistance, prrmin. At each half-day, there is a 27%
chance a patient will begin antibiotic therapy. Bintz et al. [5] chose this value as the baseline
so that the simulated total number of antibiotic treatments per patient matched the data.
The baseline values for the probabilities of receiving a low-risk, high-risk, or very-high-risk
antibiotic were taken from the dataset to be 0.4, 0.26, and 0.34, respectively.
The probability of effectively cleaning a room is set to a baseline value of 0.5, described
more in Section 3.8.6. Symptomatic patients are screened for CDI, and the sensitivity of this
test is a global variable set to 0.91. The turnover time for this test is assumed to be 2 half
days [69]. The probability of successfully treating a patient with CDI has a baseline value
of 0.8, based on the dataset from Barnes-Jewish Hospital.
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Table 3.12: Global variable explanations and baseline values
Global Variable Description Baseline value
occupancy hospital occupancy level 0.85
ar probability a patient is resistant upon admission 0.75
as probability a patient is susceptible upon admission 0.09
ac probability a patient is colonized upon admission 0.15
ad probability a patient is diseased upon admission 0.01
immcomp-prob
probability a colonized patient will not mount an
immune response
0.1
prrmin minimum probability of regaining resistance 0.2
prob-antib
half-daily probability of a patient beginning an
antibiotic treatment
0.27
prob-low-risk
probability of a prescribed antibiotic being low-risk
with respect to CDI
0.4
prob-high-risk
probability of a prescribed antibiotic being high-
risk with respect to CDI
0.26
prob-vhigh-risk
probability of a prescribed antibiotic being low-risk
with respect to CDI
0.34
phl
probability of becoming colonized if treated with
low-risk antibiotic in a highly contaminated room
1/30
prob-eff-clean probability of effective room cleaning 0.5
sensitivity sensitivity of the CDI screening test 0.91
turnover turnover time (half-days) of the CDI screening test 2
prob-succ-treat probability of successful treatment of CDI 0.8
hcw-contact-
compliance
probability of an HCW following proper contact
precautions when visiting a quarantined patient
0.6
hcw-compliance
probability of an HCW effectively sanitizing after
visiting a non-quarantined patient
0.45
clean-reduction
proportion by which the contamination level of a
room is reduced after effective cleaning
0.5
hcw-transfer-percent
proportion of an HCW’s carrier level that is
transferred to a room upon successful transfer
0.9
room-transfer-
percent
proportion of a room’s contamination level that is
transferred to an HCW upon successful transfer
0.1
contam-level-low
maximum contamination level of a low-
contamination room
0.4
contam-level-med
maximum contamination level of a medium-
contamination room
0.8
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3.7.4 Process overview and scheduling
Our model runs some processes with a 15-minute time-step and other processes with a half-
day time-step. The following HCW processes occur every 15 minutes: first, some HCWs
may begin a new shift, and all HCWs will perform tasks on patients. Type 1 HCWs will
move from room to room every 15 minutes, and Type 2 HCWs will move every 45 minutes
(3 time-steps). Once an HCW enters a room, the risk level of the task he or she will
perform is determined. Then, the probability of an HCW transferring pathogen to a room
and the probability of a room transferring pathogen to an HCW are determined. Based on
these probabilities, HCW carrier levels and room contamination levels are updated. After
HCWs leave a room, they can reduce their contamination levels if they effectively wash their
hands. Finally, a shift change occurs, and those who have finished their shift will leave the
hospital before the process starts again. After the shift change, HCW time characteristics
are updated.
Patient behaviors and interactions are updated each half-day in the following order:
patients are admitted, their disease status is updated, the room contamination levels are
then updated based on contributions from asymptomatic and symptomatic patients, and
then patients may be discharged. Upon discharge, vacant rooms are then cleaned. Lastly,
time characteristics are updated for the patients.
3.7.5 Initialization
The hospital is initially populated by patients whose disease statuses are based on the
proportions ar, as, ac, and ad given in Table 3.12. There are 210 available rooms that are
filled to 85% occupancy. This occupancy proportion remains constant because we set the
number of patients admitted each half-day equal to the number of patients discharged in the
previous half-day. The number of HCWs is chosen so that there is a 3:1 ratio of patients to
HCWs, and this is kept constant by assuming the number of HCWs who begin their shifts at
each 15-minute time-step equals the number of HCWs who left at the last time-step. Initial
room contamination levels are based on the disease status of the patient in the room upon
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initialization, and the initial carrier level of all HCWs is assumed to be zero. The shift-
lengths of HCWs who initially populate the model are set to random lengths between 0 and
12 hours since we assume that not all of them arrived to work at the same time. We simulate
a three-week time period before recording any outputs to ensure that initial conditions are
not significantly affecting the results.
3.8 Submodels
In this section, we detail all the submodels that together form the overall simulation routine.
3.8.1 Admit HCWs
At the beginning of each 15-minute time-step, new HCWs arrive to replace those who left
the hospital at the end of the previous time-step. The number who arrive is set equal to
the number who left at the previous time-step to ensure that the ratio of 1 HCW to every 3
patients is maintained. Upon arrival, each HCW is randomly assigned to a ward, and he or
she remains in that same ward for the entirety of the shift. HCWs are only initially admitted
into patient-occupied rooms where no other HCWs are currently present.
Once a new HCW arrives to the hospital, he or she is assigned a Type 1 or Type 2 role
with a 50% chance of each. Additionally, a HCW’s pathogen level is set to 0 upon arrival,
and he or she is assigned a length of shift. For simplicity, we consider two possible shift
lengths: 8 hours or 12 hours. There is a 50% chance a HCW will work an 8-hour shift, and a
50% chance he or she will work a 12-hour shift; this is decided for each HCW once arriving
to the hospital.
3.8.2 Admit patients
This subroutine is modeled in the same way as that described in [5] with small modifications.
At the beginning of each half-day time-step, new patients are admitted to replace those
discharged at the end of the previous time-step. Similar to the arrival of HCWs, the number
of new patients admitted equals the number of patients discharged at the previous time-step
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to maintain a constant total population. Because of the variability in the number of patients
discharged at the end of each time-step, this also ensures consistency and keeps the number
of patients lower than the total number of ward rooms. The assignment of disease status
upon admission is determined with the same probabilities used in the initialization process:
ar, as, ac, and ad, listed in Table 3.12. That is, there is a 75% chance an admitted patient
is resistant [45], a 9% chance an admitted patient is susceptible, a 15% chance an admitted
patient is colonized [1], and a 1% chance an admitted patient has CDI [45]. After a patient
is assigned a disease status, we set his or her time since entering this disease status to 0 so
that we can track this throughout the patient’s hospital stay. The only exception to this
is for resistant patients; we do not track their time since becoming resistant since this time
does not affect their probability of moving to another disease class or how long it will be
until they move to another disease class.
When patients are admitted, we initialize their number of antibiotics received in the
hospital to 0, and their time since admission is also set to 0. Patients are randomly assigned
a room upon admission and will only be assigned to vacant rooms since we assume all hospital
rooms are single patient rooms. Also upon arrival, each patient is assigned a length of stay,
which is determined by the subroutine described in Section 3.8.16.
When a patient is admitted as susceptible, we first assign that patient an antibiotic
history because of our assumption that the only way to become susceptible to colonization
is through the disruption of the normal gut microbiota by antibiotics. The process for
determining the type of antibiotic that we will assign is described in Section 3.8.12. We next
assign the susceptible patient a time since beginning antibiotic treatment (which will vary
since antibiotic treatment began prior to entering the hospital). As described in [5], we set
this time to “a random integer drawn from a uniform distribution ranging from 0 to an upper
limit defined as the sum of the treatment length (14 half-days) and time until microbiota
recovery (28 half-days for low- and high-risk antibiotics and 70 half-days for very-high-risk
antibiotics).” This mimics our assumption that patients become susceptible immediately
after receiving antimicrobial treatment and remain susceptible until the restoration of their
normal gut microbiota. Lastly, a susceptible patient’s time since becoming susceptible is set
equal to his or her time since beginning an antibiotic.
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Upon admission of a colonized patient, we first must determine whether or not this patient
is immunocompromised. We do so by using the global variable for the probability a colonized
patient will not mount an immune response, listed in Table 3.12. Once it is determined that
a patient is not immunocompromised, we then assign the patient an antibiotic, using the
subroutine described in Section 3.8.12. Next, we assign a time since beginning antibiotics in
the same way described in the previous paragraph for susceptible patients. Because these
patients can become colonized anytime after receiving an antibiotic, we lastly set their time
since becoming colonized to be a random integer chosen from a uniform distribution ranging
from 0 to their time since beginning antibiotics.
If it is determined that a colonized patient is immunocompromised upon admission,
this patient will contract CDI, and the time until doing so is referred to as the incubation
period. The length of the incubation period for a particular patient depends on the risk
level of the antibiotic assigned. Therefore, for each immunocompromised patient, we begin
by assigning an antibiotic (Section 3.8.12). The minimum and maximum possible lengths of
the incubation period for various antibiotic-risk levels are given in Table 3.10. In particular,
for those patients assigned a low-risk antibiotic, their incubation period is assigned to be a
random integer from a uniform distribution over 20 to 60 half-days. Patients on a high-risk
antibiotic have a greater chance of contracting CDI more quickly, so they are assigned an
incubation period ranging from 14 to 40 half-days while patients on very-high-risk antibiotics
are assigned an incubation period between 8 and 20 half-days. Once an immunocompromised
patient is assigned an incubation period, he or she is then assigned a time until becoming
diseased, which we set to a random integer less than or equal to the incubation period.
Lastly, we track their time since becoming colonized by setting it equal to the length of the
incubation period minus the time until becoming diseased, as described in [5].
If a patient is diseased upon admission, we begin by setting his or her time since becoming
diseased to be a random integer less than or equal to 21 half-days, as used in [5]. We then
assign whether or not each diseased patient will be treated successfully by using the global
variable for the probability of successful treatment, listed in Table 3.12 as 0.8 [57]. Next, we
decide if the hospital will successfully identify a diseased patient as diseased upon screening.
Note that all patients are screened upon admission and/or upon becoming diseased [5]. The
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success of the screening depends on the sensitivity of the test for CDI, which we represent
with the sensitivity global variable listed in Table 3.12 as 0.91 [69]. If a patient will be
successfully identified as diseased, we initialize his or her time since a successful screening to
0. Similarly, we will set the time since an unsuccessful screening to 0 for those patients who
are not successfully identified. The turnaround time for the test is set to be 2 half-days [69];
once a patient’s time since a successful screening reaches this turnaround time, he or she
will be quarantined and begin treatment for CDI, a procedure described in Section 3.8.15.
Those diseased patients who were unsuccessfully screened for CDI will not be tested again
until after the turnaround time has passed.
3.8.3 Update disease status
This subroutine is run at each half-day time-step and is implemented similarly to the update-
disease-status procedure described in [5]. There is a global variable for the probability that
a patient will receive an antibiotic each half-day. In [5], they determined this probability
should be 0.27 so that the total number of antibiotic treatments per patient matched the
data from Barnes-Jewish Hospital. All possible disease-status transitions for a patient are
illustrated in Figure 3.2 and were briefly described in Section 3.7.3. In this section, we
describe in more detail the transitions and how they are implemented.
Once patients transition to a new disease status, their time since entering this new status
is set to 0. A resistant patient’s only possible movement is to the susceptible class by taking
an antibiotic. If it is determined that a resistant patient receives an antibiotic, then that
patient will be assigned an antibiotic (Section 3.8.12). We also keep track of the number of
antibiotics a patient receives while in the hospital, so we update this number here. Next, an
updated length of stay will be determined based on the patient’s new status as susceptible;
more details about this are given in Section 3.8.16. If this updated length of stay is greater
than the current length of stay assigned to the patient, then the patient’s current length of
stay will be modified to reflect the longer length of stay.
A susceptible patient can either move back to the resistant class or become colonized
after being exposed to pathogen. For each susceptible patient, this subroutine begins by
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determining his or her probability of regaining resistance, which varies at each half-day time-
step. Details about the calculation of this probability are given in Section 3.8.14. Based on
this probability, a susceptible patient may return to the resistant class. If a susceptible
patient does not return to resistant, there is a 27% chance that he or she will receive an
additional antibiotic, and the type of antibiotic received is determined by the procedure
described in Section 3.8.12.
Each susceptible patient also has a probability of becoming colonized that depends on the
local contamination level and on the risk level of the antibiotic(s) received. Details about the
calculation of this probability are given in Section 3.8.13. We also keep track of the number
of patients who become colonized while in the hospital. If it is determined a susceptible
patient will become colonized, we count him or her in this list and then determine whether
or not he or she will be immunocompromised. For those who are immunocompromised,
their incubation period is set in the same way as described in the admit-patients subroutine
(Section 3.8.2).
For those colonized patients who are not immunocompromised, they also have a
probability of regaining resistance (Section 3.8.14), or, like susceptible patients, they may
receive an additional antibiotic. If so, their total number of hospital antibiotics and time
since beginning an antibiotic are updated to reflect this.
Colonized patients who are immunocompromised also have a chance of receiving an
additional antibiotic. Once the type of antibiotic is determined, this additional antibiotic
may decrease their incubation period. In particular, for a high-risk antibiotic, their time
until becoming diseased is decreased by 10%, and for a very-high-risk antibiotic, their time
until becoming diseased is decreased by 20%. Once their time until becoming diseased
reaches 0, they move to the disease class and receive an updated length of stay based on
this new disease status (Section 3.8.16). Now that these patients are symptomatic, they will
be screened at the next half-day time-step. We then determine whether these patients will
be treated and/or screened successfully (in the same manner as described in Section 3.8.2).
These patients are then counted in the number of patients who become diseased while in the
hospital.
The only possible transition for diseased patients is back to the susceptible class. If a
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diseased patient had a successful screening, he or she will be quarantined and begin treatment
once the turnover time for the screening test has elapsed. If it is determined that the
treatment will be successful, then the diseased patient may move back to the susceptible
class after 20 half-days [5]. If a diseased patient had an unsuccessful screening, then after
the turnover time has elapsed, he or she will be re-screened for CDI.
3.8.4 Update room contamination levels
After patient disease statuses are updated, the model updates the room contamination levels
based on the disease status of the patient in the room. This particular subroutine only
considers patient contributions to overall room contamination levels; HCW contributions are
updated every 15 minutes using a different submodel (Section 3.8.9). A colonized patient
will contribute an amount in the range [1, 2) to the room contamination level at each half-
day time step. Because the transmission potential is higher for patients with active disease
than in asymptomatic carriers [26], a diseased patient will contribute an amount in the range
[2, 3) at each half-day time-step. Note that these ranges are larger than the possible ranges
for HCW contributions since HCW contributions are updated at every 15-minute time-step.
3.8.5 Discharge patients
Once a patient’s time since being admitted reaches his or her length of stay (assigned upon
admission based on the procedure described in Section 3.8.16), that patient is discharged
from the hospital. Discharges can only occur at each half-day time-step. In the discharge
subroutine, we also tally the total number of patients discharged, the total number of patients
discharged for each disease status, and the total number of antibiotics given in the hospital.
The average length of stay for all discharged patients is also calculated.
3.8.6 Clean ward rooms
After patients are discharged, their vacant room is cleaned. The probability the room will
be effectively cleaned is a global variable, listed in Table 3.12 as 0.5. This baseline value
was chosen because, depending on which cleaning measures are used, the cleaning could be
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more or less effective, and this probability can be adjusted to mimic more or less intensive
cleaning. Our model only explicitly accounts for terminal cleaning; however, daily cleaning
of select rooms could be implemented in the case of an outbreak. This can be incorporated
in our model by modifying the contamination level of rooms that were targeted by extra
cleaning.
In this subroutine, if it is determined a room will be effectively cleaned, the contamination
level of the room will decrease by 50%, which is represented by the global variable clean-
reduction. Similar to the probability of effective cleaning, this percentage can be increased
to model more targeted and intensive cleaning.
3.8.7 Update patient time characteristics
Patient time characteristics are updated at each half-day time-step. This includes their time
since being admitted and, for all patients except resistant patients, their time since entering
their current disease status. As mentioned in Section 3.8.2, we do not track this time for
resistant patients because it does not affect whether or not they will become susceptible;
this is only determined by their probability of receiving an antibiotic.
For susceptible and colonized (non-immunocompromised) patients, this submodel in-
creases their time since beginning an antibiotic by one half-day time-step each time it is
run. For the colonized (immunocompromised) patients, their time until becoming diseased
is decreased by one half-day. We also update the time since a diseased patient has received
a successful, or unsuccessful, screening for CDI, and for those diseased patients who have
begun treatment, we update their time since beginning treatment.
3.8.8 HCW movement
This subroutine defines how HCWs move from room to room, which depends on whether
or not they are Type 1 HCWs or Type 2 HCWs. HCWs are instructed to only move into
rooms that are currently occupied by a patient and will never enter vacant ward rooms. We
also assume that all HCWs remain in the same ward for the entirety of their shift and never
move from ward to ward.
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In each ward, the rooms are numbered from 1 to 35. Type 1 HCWs, skipping any rooms
that are unoccupied, move every 15-minute time-step from one room to the next in order of
room number. Upon reaching room 35, a Type 1 HCW will next move to room 1 of that
ward (as long as it is occupied at that time). Type 2 HCWs move randomly within a ward,
and only move every three 15-minute time-steps. It is not possible for two Type 1 HCWs to
be in the same room at the same time or for two Type 2 HCWs to be in the same room at
the same time; however, it is possible for a Type 1 and a Type 2 to visit the same patient
at the same time.
3.8.9 Update HCW and room contamination levels
This subroutine defines both how an HCW will transfer pathogen to a room and how an
HCW will pick up pathogen from a room. It has three parts: defining risk level of tasks being
performed, determining the probability of transfer, and updating contamination levels based
on that transfer. Note that in our model there is no direct pathogen transfer from an HCW
to a patient or vice versa. This transfer pathway is indirectly considered by assuming that
colonized patients shed pathogen and increase the contamination level of their rooms, and
the contamination level of the room affects the probability of HCWs picking up pathogen
from that room.
The submodel begins by determining the risk level of the task each HCW will perform at a
particular time-step. Type 1 HCWs have a greater chance of performing low-risk tasks while
Type 2 HCWs have a greater chance of performing high-risk tasks. The specific probabilities
used are shown in Table 3.13. The risk level of the task is chosen at every 15-minute time-
step for both Type 1 HCWs and Type 2 HCWs. Therefore, a Type 2 HCW may perform
different risk level tasks while with the same patient.
After determining the task-risk level, this submodel determines both the probability that
an HCW will transfer pathogen to a room and the probability that a room will transfer to
an HCW. Both of these probabilities depend on the risk level of the task being performed
and on the amount of contamination already in the room or on the HCW’s hands. We use
three transfer functions, one for each risk level, to determine these probabilities. Each is a
function of the following form, where x represents the contamination level (of the room or
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of the HCW) and k depends on the risk level of the task:
f(x) =
1− exp
(−x
k
)
1 + 300 exp
(−x
k
) .
The value of k controls the steepness of the curve. In particular, we use k = 1, 0.5, and 0.15
for a low-risk, medium-risk, and high-risk task, respectively. The resulting transfer functions
are shown in Figure 3.20. The higher the contamination level of the HCW (or the room), the
higher the probability of transfer. For a high-risk task, there is a greater chance of transfer
at lower contamination levels than there is for a medium-risk or low-risk task at the same
contamination level. Note that this process is only used for non-quarantined patients. For
those patients who are quarantined, there is either a 100% chance of transfer or a 0% chance
of transfer, depending on the variable hcw-contact-compliance. As listed in Table 3.12, we
set this value to 0.6 [75] since HCWs are more likely to comply with proper contact protocol
when visiting a quarantined patient. When an HCW does comply with contact regulations
with a quarantined patient, then there is a 0% chance of pathogen transfer; when an HCW
does not, there is a 100% chance of transfer.
The final process in this submodel involves the actual transfer of pathogen. If is
determined that an HCW will transfer pathogen to the room, then he or she will transfer
90% of his or her total contamination level to the room. This then decreases the HCW
contamination level by 90% and increases the room contamination level by that same amount.
This percentage is represented by the global variable hcw-transfer-percent listed in Table 3.12.
Similarly, if it is determined that a room will transfer pathogen to an HCW, then the room
contamination level will decrease by 10%, and the HCW contamination level will increase
by that amount. This value for room-transfer-percent was chosen with the assumption that,
because a room has many surfaces on which pathogen may live, one HCW will only pick up
a small percentage of the total contamination in one visit.
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Table 3.13: Probabilities used to determine risk level of tasks performed by HCWs
Type 1
Task Risk Level Probability
low 0.60
medium 0.25
high 0.15
Type 2
Task Risk Level Probability
low 0.15
medium 0.25
high 0.60
0 1 2 3 4 5 6 7 8 9 10
Contamination Level (of HCW or Room)
0
0.1
0.2
0.3
0.4
0.5
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Figure 3.20: Transfer functions used to determine the probability a room (or HCW) will
transfer pathogen at a particular time-step
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3.8.10 HCW compliance
Each time HCWs leave a room, they wash their hands with a 45% chance of effectively doing
so [75]. Based on this probability, if it is determined they will effectively do so, they reduce
their total contamination level to 5% of what it was prior to washing their hands. If not,
their contamination level remains the same.
3.8.11 Shift change and update of HCW time characteristics
Once an HCW’s time since beginning a shift reaches the total length of his or her shift,
assigned upon arrival (Section 3.8.1), he or she will leave the hospital. After this, we update
the counter tracking the time since each HCW’s shift began before starting the next 15-
minute time-step.
3.8.12 Antibiotic assignment
The degree of microbiota disturbance (and resulting susceptibility to colonization) caused by
antibiotics depends on the spectrum, duration, and number of antibiotics received [78, 14, 5].
For this reason, we maintain the three risk levels for antibiotics defined in [5]: low risk, high
risk, and very high risk. This categorization of antibiotics was based on studies completed to
analyze the association of particular antibiotics with C. difficile. In the antibiotic assignment
submodel, we assign an antibiotic-risk level based on the probabilities of the antibiotic being
low risk, high risk, or very high risk in terms of its association with C. difficile. The baseline
values for these probabilities are given in Table 3.12. The risk level of an antibiotic also
affects the time until microbiota returns to normal, which we assign in this subroutine based
on the risk level assigned. For all patients, we set the length of treatment to one week as a
simplifying assumption also used in [5].
3.8.13 Colonization probability assignment
At each half-day time-step, a susceptible patient’s probability of being exposed to C. difficile
and becoming colonized depends on two things: the contamination level of the room and
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the risk level associated with the antibiotic received. To determine this probability, we
divide room contamination levels into three categories: low, medium, or high contamination.
Together with the three antibiotic-risk levels (low, high, or very high), this makes nine
possible combinations of antibiotic-risk and room-contamination levels, which gives us nine
different probabilities of colonization.
We denote plh to represent the probability of a susceptible patient becoming colonized
given that he or she is in a room with low contamination and has received a high-risk
antibiotic. We use this notation similarly for the eight remaining probabilities, where the
superscript refers to the room contamination level (l, m, or h) and the subscript refers to
the risk level associated with the antibiotic (l, h, or vh).
To determine values for each of these probabilities, we began by using those calculated
by Bintz et al. in [5]. Because studies have quantified the odds ratios for the risk of infection
assigned to specific antibiotics [4] [23] [78], Bintz and his coauthors used odds ratios to
represent the chances of becoming colonized if given a high-risk or very high-risk antibiotic
compared to the odds of becoming colonized after given a low-risk antibiotic. Specifically,
they were able to estimate odds ratios for high-risk and very high-risk antibiotics and then
use those values, along with the data for the number of nosocomial infections, to determine
the probabilities.
In our model, we used the nine probabilities calculated in [5] as a foundation but then
modifed each of these values so that our number of nosocomial colonizations more closely
matched the dataset. To make this match, we divided the nine probabilities used by Bintz
et al. by the same scaling factor so that nosocomial colonizations accounted for 20% of all
admissions [11, 40]. The final values we used for the probabilities are given in Table 3.14.
3.8.14 Resistance-restoration probability assignment
Once the microbiota returns to normal, a patient’s resistance to colonization by C. difficile
is restored. The chances of regaining resistance depend on how long a patient has been on
an antibiotic and the type of antibiotic the patient received since the associated antibiotic
risk affects the length of time until a normal microbiota is restored.
To determine the probability that resistance will be restored for a patient at a particular
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Table 3.14: Probabilities of becoming colonized for each combination of antibiotic-risk and
room-contamination level
Antibiotic Risk Level Room Contamination Level Value
phl low high 0.0333
phh high high 0.0920
phvh very high high 0.1301
pml low medium 0.0250
pmh high medium 0.0748
pmvh very high medium 0.1119
pll low low 0.0167
plh high low 0.0544
plvh very high low 0.0874
time-step, we use the same function Bintz et al. use in [5]. This function is logistic, where
the input t represents the time since a patient began taking an antibiotic and T is the sum
of the treatment length and the time until a normal microbiota is restored:
p(t, T ) =
1− pmin
1 + exp
(−12
T
(
t− T
2
)) + pmin.
The variable pmin is set to 0.2 and represents the minimum probability of regaining resistance
while the parameter value of 12 controls the steepness of the curve.
3.8.15 Quarantine and treat
This submodel allows us to identify those patients who were successfully screened for CDI,
mark them as quarantined, and model the effects of their isolation. Once patients are
quarantined, they begin antimicrobial treatment for CDI, so we assign them an antibiotic
using the procedure described in Section 3.8.12. Then, we update the patient’s total number
of hospital antibiotics to reflect this and initialize the time since beginning treatment to 0.
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3.8.16 Patient length of stay
Depending on their disease status at admission, patients’ length of stay in the hospital will
vary. We assign patients a length of stay upon admission (Section 3.8.2) and determine
this length in the same manner used in [5]. In their model, the authors resampled from the
dataset generated by the Barnes-Jewish Hospital values for the length of stay of patients
in each particular disease status. They then determined that resistant patients will stay
between 0 and 16 days, susceptible and colonized patients will stay between 0 and 34 days,
and diseased patients will stay between 0 and 80 days.
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Chapter 4
Future work
The results we obtained in Chapter 2 are only a starting point for the analysis of vaccination
against CDI. Because such a vaccine is still in testing, we were unable to incorporate data
for quantities such as the monetary cost associated with this vaccination program. Once this
data is obtained, we hope to carry out a more quantitative modeling study.
Additionally, the form of vaccination implemented in the ABM presented in Chapter 3
was based on the following assumptions: (1) everyone who needed to be vaccinated was able
to be and (2) the vaccine was successfully implemented in such a way that the hospital
experienced an overall reduction in the percentage of colonized, immunocompromised
patients. Will vaccination actually result in the overall decrease in the percentage of
colonized, immunocompromised patients that we assumed in Chapter 3? We would like
to weaken our assumptions and observe how modeling and tracking the vaccination of
individual patients in the ABM affects the overall disease prevalence. In particular, we
want to incorporate age and other CDI risk factors when deciding who to vaccinate.
Future plans also include expanding our exploration of the role environmental reservoirs
play in C. difficile transmission. Specifically, we will examine the effect of fomite touch
frequency on transmission. To model these dynamics, we will utilize a stochastic model that
incorporates patient and pathogen populations, where the patients are divided according
to disease status with respect to C. difficile and the pathogen levels are divided based on
high-frequency touch surfaces and low-frequency touch surfaces. Our goal is to use this
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model to better understand how surfaces with varying touch frequencies affect nosocomial
colonizations and infections by C. difficile.
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A Sensitivity analysis
Sensitivity analysis is used to quantify uncertainty by evaluating how variations in model
outputs can be attributed to different input sources, such as parameter values and initial
conditions [54, 76]. Because a few of our parameters in Chapter 2 were numerically estimated
and did not come directly from data or the literature, it is useful to quantify the impact
of each of our parameters on the objective functional value, J(v∗), in (2.8). If our output
is notably sensitive to a particular parameter value, it becomes more important for us to
estimate that parameter as accurately as possible.
We use Latin Hypercube Sampling (LHS) and partial rank correlation coefficients
(PRCCs) to perform our sensitivity analysis. LHS is a sampling technique that requires
fewer samples than many other sampling methods, but with equivalent accuracy [54]. This
sampling process involves taking the assigned interval for each parameter, dividing it into
n intervals of equal probability, and then sampling each of the intervals to obtain n values
for each parameter. We then use the vector of n values for each of the k parameters being
evaluated to create an n× k matrix, referred to as the LHS matrix. As a result, the ith row
of the LHS matrix contains a specific value for each of the k parameters to be used on the
ith run of the computer model.
For our analysis, we aim to quantify the impact of 11 inputs, in this case parameter
values, on the objective functional value J(v∗). The 11 parameters of interest are listed, with
their corresponding baseline values and intervals sampled, in Table A.1, and we assume the
parameters are uniformly distributed across the their specified intervals, which were chosen
so that the baseline value used in Chapter 2 is the average of the lower and upper bound of
the interval. For LHS to be used correctly, it is required that the output be monotonic with
respect to each of the parameters [59]. Before begin the sampling process, we ensure that
this monotonicity requirement is met for each parameter, and any parameter that does not
satisfy this criteria cannot be included in the sensitivity analysis. To verify monotonicity,
we vary one parameter while fixing the remaining parameters at baseline and then solve our
optimal control problem several times across the assigned interval for the parameter being
varied. We were able to illustrate that the objective functional value J(v∗) was monotonic
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with respect to each of the 11 parameters being considered.
Next, we created the n × 11 LHS matrix. The number of trials, n, that we used was
100. Each column of our LHS matrix then represents 100 different values for a particular
parameter that were chosen from 100 different subintervals of equal probability between
the lower bound and upper bound for that parameter. The 100 chosen values for each
parameter are permuted so that they are randomly ordered. Each row of the LHS matrix
then represents one particular parameter combination to be used to solve our optimal control
problem and then to calculate the resulting objective functional. Thus, we solve the optimal
control problem 100 times for 100 different parameter combinations contained in each row
of the LHS matrix.
Correlation quantifies the strength of a linear association between an input and an output
while controlling for the impact of the remaining inputs [54] . We calculate PRCCs for each of
our parameters and then use significance tests to assess if the PRCC is significantly different
from zero and if two PRCCs are significantly different from each other. To calculate the
PRCCs and corresponding p-values of the significance tests, we use the partialcorr() function
in MATLAB. The resulting values are illustrated for easy comparison in Figure A.1 and are
listed in Table A.2.
Using a significance level of 0.01, we conclude that α, βc, βd, kr, and k have PRCCs
that are significantly different from 0. Thus, the antibiotic prescription rate, transmission
coefficients (for both asymptomatic and symptomatic patients), and discharge rates for all
patients except diseased patients have a significant impact on the objective functional value
J(v∗).
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Table A.1: List of parameters considered in the sensitivity analysis procedure with their
corresponding intervals sampled and baseline values
Parameter Interval Baseline value
α [0.35, 0.65] 0.5
θ [0.023, 0.043] 0.033
βc [10
−8, 10−4] 10−6
βd [10
−8, 10−4] 10−6
f [0.45, 0.75] 0.6
ε [0.07, 0.13] 0.1
p [0.6, 1] 0.8
φ [0.03, 0.1] 0.06
kr [0.23, 0.43] 0.33
k [0.105, 0.195] 0.15
kd [0.048, 0.088] 0.068
-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1
c
d
f
p
k
r
k
kd
Figure A.1: Resulting PRCCs for each of the parameters considered
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Table A.2: PRCCs and corresponding p-values for each parameter
Parameter PRCC p-value
α 0.54 < 0.01
θ -0.18 0.08
βc 0.99 << 0.01
βd 0.76 < 0.01
f -0.12 0.28
ε -0.10 0.34
p -0.18 0.09
φ 0.03 0.81
kr 0.64 < 0.01
k -0.63 < 0.01
kd -0.18 0.10
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